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CHAPTER ONE
INTRODUCTION
Abstract
Diabetes affects 25.8 million Americans; more than 60% of these patients
develop neuropathy. One consequence of hyperglycemia is altered excitability
and increased calcium channel function, including an alteration of CaV3.2 (α1H) Ttype channel properties.

The changes in neuronal excitability induced by

diabetes play a central role in development of complications such as diabetic
neuropathy, given that calcium channels are crucial for cell excitability and the
initiation of action potentials and oscillatory activity.

Several groups have

reported that hyperglycemia alters CaV3.2 channel function, causing an increase
in current density, among other changes. To date, no studies have addressed a
mechanism for the observed changes. The objective of this study was to
understand the molecular changes underlying increased CaV3.2 channel function
in hyperglycemia in vitro. I probed two possible mechanisms: changes to the
glycosylation status of proteins such as CaV3.2, and indirect changes resulting
from altered plasma membrane composition. In aim one, I investigated if excess
N-acetylneuraminic

acid

moieties

affect

Cav3.2

channel

function

in

hyperglycemia. We hypothesized that in hyperglycemia, excess glucose entering
the hexosamine pathway results in increased protein glycosylation – including
1

2
the α1H subunit – which could lead to enhanced current density. I analyzed
changes in current density and biophysical properties after using neuraminidase
to cleave extracellular-facing sialic acids in membrane lipids and proteins,
including α1H. Culture in hyperglycemia was associated with a 150% increase in
α1H current density, likely due to an underlying increase in the channel’s open
probability.

Treatment with neuraminidase reversed the increase in current

density and open probability. Additionally, neuraminidase treatment exposed a
shift in channel availability. These results show that hyper-glycosylation of the
channel and/or membrane lipids affect channel function
In aim two I investigated the modulation of CaV3.2 by GM1, an abundant
ganglioside in the nervous system.

The proportion of GM1 in the membrane

decreases in hyperglycemia, thus we hypothesized that this change alters α1H
function. I studied whether addition of GM1 or its specific blockade with cholera
toxin subunit B alters CaV3.2 currents or their biophysical properties.

GM1

replenishment reversed the increase in current density seen in hyperglycemia.
Addition of CtxB reversed the effects of GM1, showing that this ganglioside acts
as a specific inhibitory modulator of CaV3.2. The increased open probability that
was associated with hyperglycemia was not reversed by GM1, suggesting that
there are multiple changes occurring during hyperglycemia that affect CaV3.2
function, such as alterations of protein N-glycosylation status and membrane
composition.

3
In conclusion, we showed that increased CaV3.2 T-type calcium function in
hyperglycemia is associated with increased sialic acid moieties attached to the
channel itself or to gangliosides in its immediate proximity in vitro. Additionally,
we showed that GM1 is a specific inhibitory modulator of the channel. Our results
suggest that both an alteration to the oligosaccharide chain attached to the
channel via N-glycosylation and membrane ganglioside composition affect
CaV3.2 function.

Literature review
Diabetes
Diabetes Mellitus is a group of metabolic disorders in which blood glucose
levels are abnormally high. The Centers for Disease Control and Prevention
estimates that 25.8 million Americans have Diabetes (CDC 2011). The three
most common types include type I, type II and gestational diabetes. Type I
diabetes mellitus is also known as insulin-dependent (IDDM) or juvenile-onset
diabetes.

Patients with this form have had autoimmune destruction of their

pancreatic β-cells, leading to the inability to produce insulin, with a subsequent
loss of blood glucose control. The exact cause of the disorder is not known,
though it is likely due to genetic predisposition, environmental factors, or a
combination of the two (Bluestone et al. 2010). Type II diabetes is also referred
to as non-insulin-dependent diabetes mellitus or NIDDM, and is usually adult-

4
onset.

NIDDM patients have declining β-cell function and peripheral insulin

resistance (Reaven 1988; Mahler et al. 1999). The disorder is heterogeneous;
however obesity is one major risk factor (Anderson et al. 2003). Gestational
diabetes occurs in 2-10% of pregnancies; women who have gestational diabetes
have an increased likelihood of developing NIDDM later in life (CDC 2011).
There are other, less common forms of diabetes; latent autoimmune diabetes in
adults or LADA is a form of the disease in which adults develop type I diabetes.
MODY (maturity onset diabetes of the young) and NDM (neonatal diabetes
mellitus) develop during early adulthood or in the first few months of life,
respectively, due to a single mutation that limits insulin production. In individuals
with chronic pancreatitis, cystic fibrosis, or other pancreatic diseases, damage
can lead to decreased insulin secretions. Finally, diabetes can also develop due
to infection, chemical exposure, malnutrition, and endocrine disorders.

Complications of diabetes
Diabetes is a chronic disease that greatly affects many bodily systems,
and is now the 7th leading cause of death in the United States.

Common

complications include hypertension and increased risk for heart disease and
stroke. Diabetes increases the risk for kidney and periodontal disease and is the
leading cause for blindness and amputations. It also greatly affects the nervous
system; in particular, 60% to 70% of diabetic patients develop various forms of
nervous system damage (CDC 2011), a condition known as diabetic neuropathy.

5
The most common form of nervous system damage in diabetic patients is
distal symmetric neuropathy. Patients experience heightened sensitivity to pain
(hyperalgesia), pain caused by normally non-noxious stimuli (allodynia), and
other abnormal sensations such as tingling and numbness (paresthesia).
Although some patients experience complete resolution of pain over time, most
do not; clinical studies reveal variability in the incidence of neuropathic pain in
diabetic patients. For instance, in a study that followed 86 patients with NIDDM
for 10 years, approximately 20% reported having neuropathic pain and
approximately 30% reported paresthesias. In another clinical report, researchers
saw 36 patients, none of whom had decreased neuropathic pain after four years
(Boulton et al. 1983). In a third study, only seven out of 30 patients with diabetic
neuropathy were completely pain free after a five year period (Daousi et al.
2006).
Heightened sensitivity to pain is partly due to altered synaptic transmission
and enhanced excitability of sensory neurons that results from increased voltagegated calcium channel activity.

Voltage-gated calcium channels
Voltage-gated calcium channels (VGCCs) are transmembrane proteins
that allow calcium ions to permeate the membrane during depolarization; they
are present in virtually all excitable cells. The pore-forming α subunit consists of
four repeated domains (I-IV), each containing six transmembrane segments (S1-

6
S6) (Catterall 2000) (Figure 1). The S4 segment contains positively charged
amino acid residues that allow the channel to sense changes in membrane
voltage. When an appropriate change in membrane voltage occurs, the pore
loop region (S5-S6) of each domain changes conformation, selectively allowing
Ca2+ ions to permeate the membrane.
There are several types of VGCCs; they are classified based on the
pharmacological and physiological properties of the channels and on the gene
encoding the α subunit gene (Table 1). Most basically, VGCCs are broken up
into two groups based on the voltage at which they activate. They may either be
high- or low-voltage activated (HVA or LVA, respectively) (Piedras-Renteria et al.
2007). The HVA channels include the CaV1 (L-type) and CaV2 (P/Q-, N- and Rtype) channels.

LVA channels include the CaV3 (T-type) channels (Catterall

2000). The T-type channel family contains three members: CaV3.1, 3.2 and 3.3,
also known by their principal subunit as α1G, α1H, and α1I (Cribbs et al. 1998;
Perez-Reyes et al. 1998; Lee et al. 1999; Perez-Reyes 2003). VGCCs are also
classified by their trafficking, regulation, and biophysical properties. The T-type
channel family is unique in that it does not require the co-expression of auxiliary
subunits for optimal activity in vitro, and it is thought that this family of channels
does not require auxiliary subunits for normal function in vivo. In spite of this, coexpression of T-type calcium channels with β or γ auxiliary subunits in cell lines
or xenopus oocytes is associated with slight alterations in channel function and

7

A

**

*

*

B

Figure 1. Diagram of the voltage-gated calcium channel alpha subunit.

(A) Two-dimensional depiction of the α1H subunit with its four predicted glycosylation sites
shown by green stars. (B) Three-dimensional depiction of the α1H subunit as seen from the side
(left) and from the outside of the cell (right).
Glycosylation sites predicted by (Gupta et al. 2004). Figures modified from (Marban et al.
1998; Piedras-Renteria et al. 2007)
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Channel Type

Gene

CaV1.1

CACNA1S

CaV1.2

CACNA1C
L

CaV1.3

CACNA1D

CaV1.4

CACNA1F

CaV2.1

P/Q
N

CACNA1B

CaV2.3

R

CACNA1E

CaV3.2
CaV3.3

CACNA1G
T

Singlechannel
conductance

-30 mV
and
positive

very slow

25 pS

-20 mV
and
positive

partial

13 pS

-70 mV
and
positive

complete

8 pS

CACNA1A

CaV2.2

CaV3.1

Activation
Inactivation
Range

CACNA1H
CACNA1I

Table 1. Nomenclature and properties of the voltage-gated calcium channels.
(Tsien et al. 1988)
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membrane localization (Dolphin et al. 1999; Hobom et al. 2000; Klugbauer et al.
2000; Green et al. 2001). The endogenous function of these auxiliary subunits
with relation to the T-type channels is still unknown.

T-type channel biophysical properties
VGCCs can exist in three distinct conformational states: closed, open, and
inactivated. Upon sufficient depolarization of the membrane, channels transition
from a closed state to an open state, allowing ion permeation.

If the

depolarization event is brief (not long enough for inactivation to occur), channels
can transition back to a closed state, where they can be readily re-opened with
another depolarization event.

If the depolarization event is sustained, the

channels will transition from an open state to an inactivated state in which the
pore is blocked and calcium cannot enter the cell. When in an inactivated state,
channels cannot be opened again, even upon further depolarization.

To

transition from this inactivated state back to a closed state, the membrane must
be hyperpolarized and the channels must be “reset”.
The biophysical properties with which we are concerned in this study include
the channel kinetics such as the rates of activation, inactivation, and deactivation,
as well as voltage-dependence of activation and inactivation.
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Activation
Channel activation occurs when membrane depolarization causes a
conformational change in the channel that allows calcium ions to permeate the
membrane, changing the channel from a closed state to an open state.
Changes in ion permeability due to membrane depolarization were
originally described by Hodgkin and Huxley after their experiments with squid
giant axon (Hodgkin et al. 1952). Later, it was postulated that charged particles
located within the membrane moved in response to depolarization, allowing
these permeability changes (Armstrong et al. 1973). After further study, the 4th
transmembrane domain (S4) was shown to be crucial for voltage-sensing and
thus, channel activation, in voltage-gated sodium, potassium, and calcium
channels (Tanabe et al. 1987; Stuhmer et al. 1989; Papazian et al. 1991;
Larsson et al. 1996). Positively-charged arginine residues located every third
amino acid in S4 segments of VGCCs form sequential ion pairs with negativelycharged amino acid residues in surrounding transmembrane segments, allowing
S4 to slide, rotate, and tilt out of the membrane, leading to pore opening and ion
permeation (Lam et al. 2005; Hamid et al. 2006). A similar mechanism has been
shown in voltage-gated potassium channels (Jiang et al. 2003). Using structural
data from bacterial voltage-gated sodium channels, an identical phenomenon
was shown (Yarov-Yarovoy et al. 2012). Other regions of the channel that have
been shown to be important for determining properties of channel activation
include the I-II (Vitko et al. 2007) and II-III linker (Park et al. 2004), though it has
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been postulated that there are residues existing throughout the entire structure
that influence channel activation and that these residues, as well as each subunit
or domain, must work in concert to successfully activate the channel.
Of the LVA subtypes, CaV3.1 (α1G) activates approximately 1.5 times more
quickly than CaV3.2 (α1H), and approximately 5 times more quickly than CaV3.3
(α1I) (Klockner et al. 1999; Chemin et al. 2002). In a study where chimeras of full
domains from CaV3.1 and CaV3.3 were made, simply switching domain IV
between the two subtypes could almost entirely confer activation properties of
the opposite channel subtype (Hamid et al. 2006).
Activation can be measured in voltage-clamp electrophysiology by
stepping the voltage from the holding potential to various test potentials for a
period of time that is just long enough to observe the peak current. A single
exponential function in the form Aie-t/τi + C is fit to the negative-going portion of
the curve. Ai represents the rate constant, t represents the time interval, τi
represents the time constant, and C represents the steady-state asymptote.

Steady-state activation
Steady-state activation is a representation of channel activation at
different voltages. This information indicates the probability that channels in a
population will be open when the membrane is depolarized to a given voltage.
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Similar to kinetics of activation, S4 segments are implicated in the voltagedependence of channel activation in shaker potassium channels (so named for
the gene’s mutant phenotype in Drosophila melanogaster) (Lopez et al. 1991;
Papazian et al. 1991; Larsson et al. 1996) and in sodium channels (Auld et al.
1990).

The S4-S5 linker is also implicated in shaker potassium channels

(McCormack et al. 1991).

In the HVA calcium channels, the S5 and S6

segments of domains III and IV (Hockerman et al. 1997; Motoike et al. 1999) are
implicated in voltage-dependent activation. In the low-voltage activated calcium
channels, the arginine residues of S4 segments are again implicated (Kraus et al.
2000; Lam et al. 2005), as well as residues in the S2-S3 and S5-S6 linkers of
domain I (Khosravani et al. 2004), the I-II linker (Vitko et al. 2007), and the S6
regions of domains II, III, and IV (Kraus et al. 2000; Marksteiner et al. 2001).
Hamid et. al broadly implicate domain IV and to a lesser extent, domain I as a
result of their chimera studies of CaV3.1 and CaV3.3 (Hamid et al. 2006). The
voltage at which half of the channels are likely to be in an open conformation,
also known as the half activation voltage, in CaV3.1 and CaV3.2 have been
measured to be more negative than that of CaV3.3 (Chemin et al. 2002), meaning
that during a depolarization event, a smaller proportion of CaV3.3 are likely to be
in an open conformation than CaV3.2 and CaV3.1.
Steady-state activation is measured by stepping the voltage from holding
potential to -30 mV briefly in order to activate channels without allowing
inactivation.

Cells are then hyperpolarized, which allows large amounts of
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calcium to enter the cell due to calcium’s electrostatic attraction to the negative
charges within the cell. Currents elicited by this protocol are specifically known
as tail currents. The peak tail current induced by each voltage is measured and
normalized to the maximum current produced.

The normalized values are

plotted and fitted with a single Boltzmann function in the form m+IMAX/{1+e^[(V50V)/k]}, where IMAX represents the maximal current, V50 represents the voltage of
half activation, k represents the slope factor and m represents the baseline
factor.

Inactivation
Channels are inactivated during sustained membrane depolarization.
During voltage-dependent inactivation (as opposed to calcium-dependent
inactivation), channels undergo a conformational change from an open to an
inactivated state in which the pore is blocked from any further ion permeation.
The channel can only reopen after the membrane is hyperpolarized and the
channel undergoes a conformational change to the closed state.
In the 1970s, Armstrong, Bezanilla and Rojas used pronase to digest
proteins on the cytoplasmic side of squid giant axons. They showed that after
digestion, sodium channel inactivation was effectively destroyed (Armstrong et al.
1973). They later went on to describe “ball and chain” or N-type inactivation, a
fast type of inactivation in which the channel pore is blocked from further ion
permeation (Armstrong et al. 1977).
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In separate studies using site-directed mutagenesis or antibodies it was
determined that the intracellular III-IV linker is crucial for inactivation in voltagegated sodium channels (Vassilev et al. 1988; Stuhmer et al. 1989; Vassilev et al.
1989). This linker acts as a hinged lid to block further ion permeation.
A similar phenomenon was observed in shaker potassium channels, in
which deletion of specific charged residues in the N-terminus destroyed
inactivation (Hoshi et al. 1990). It was later postulated that the S4-S5 loop may
be the receptor for the inactivation gate in these channels (Isacoff et al. 1991).
Several regions in voltage-gated calcium channels are implicated in
current inactivation. In addition to fast inactivation that is postulated to occur as a
result of S6 in all four domains, the II-III linker, the I-II linker , and the C-terminus
in both LVA and HVA channels (Zhang et al. 1994; Herlitze et al. 1997; Bourinet
et al. 1999; Motoike et al. 1999; Hering et al. 2000; Kraus et al. 2000; Stotz et al.
2000; Marksteiner et al. 2001; Staes et al. 2001; Stotz et al. 2001; Shi et al.
2002; Park et al. 2004; Livneh et al. 2006; Vitko et al. 2007), regions such as the
IVS3-S4 and IVS5-S6 segments in HVA channels (Hans et al. 1999), IIS2, the IIIIV linker , and domain IV (Staes et al. 2001; Khosravani et al. 2004; Hamid et al.
2006) in T-type channels may influence fast inactivation, but are more likely to be
important in slow inactivation because they are located within the membrane or
on the extracellular side of the cell. Via slow inactivation (also known as C- or Ptype inactivation), channels undergo a more permanent conformational change to
prohibit any further ion permeation. The structures involved in slow inactivation
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must be distinct from the structures involved in fast inactivation, as studies that
abolished fast inactivation with enzymes, mutagenesis, or antibodies left slow
inactivation intact (Armstrong et al. 1973; Armstrong et al. 1977).
When comparing the LVA channel subtypes, CaV3.1 has the fastest
inactivation kinetics, closely followed by CaV3.2.

CaV3.3 has much slower

kinetics (Klockner et al. 1999; Chemin et al. 2002). In fact, in a study where
chimeras of CaV3.1 and CaV3.3 were made, switching domain IV between the
two subtypes significantly altered inactivation kinetics in such a way that each
subtype functioned more like the opposite type (Hamid et al. 2006).
Channel inactivation is measured by stepping membrane voltage from the
holding potential to various test potentials for a period of time that is long enough
to observe the current plateau due to complete inactivation. Subsequently, a
single exponential function in the form Aie-t/τi + C is fit to the decaying portion of
the curve. Ai represents the rate constant, t represents the time interval, τi
represents the time constant, and C represents the steady-state asymptote.

Steady-state inactivation
Steady-state inactivation is a representation of channel inactivation at
different voltages. This information indicates the availability of channels to be
opened after a sustained depolarization event at a given voltage. In other words,
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this protocol measures the proportion of channels that are in a closed state (able
to pass current) as opposed to an inactivated state (unable to pass current).
In LVA channels, alterations to the I-II (Vitko et al. 2007) and III-IV linkers
(Staes et al. 2001), IIS2 (Khosravani et al. 2004), and the C-terminus (Staes et
al. 2001) affect the voltage dependence of channel inactivation. Similarly, in
HVA channels the I-II and II-III linkers, the IVS3-S4 and IVS5-S6 loops, and
domains IIS4, IVS5, and IVS6 are implicated in the control of voltagedependence of inactivation (Zhang et al. 1994; Herlitze et al. 1997; Bourinet et al.
1999; Hans et al. 1999; Motoike et al. 1999; Kraus et al. 2000; Stotz et al. 2000;
Livneh et al. 2006).

The S4 region is implicated in voltage-dependence of

inactivation of sodium and shaker potassium channels as well (Lopez et al. 1991;
Papazian et al. 1991; Yang et al. 1995).
Steady-state inactivation is measured by stepping the voltage from holding
potential to various voltages for an extended amount of time (1.5 seconds) in
order to allow for complete inactivation. Cells are then hyperpolarized briefly and
depolarized to -30 mV in order to activate channels that were not inactivated by
the first depolarization event. The peak current from each trace is measured and
normalized to the maximum current elicited. The normalized values are plotted
and fitted with a single Boltzmann function in the form: m+IMAX/{1+e^[(V50-V)/k]} in
which IMAX represents the maximal current, V50 represents the voltage of half
inactivation, k represents the slope factor and m represents the baseline factor.
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Deactivation
Channel deactivation occurs when the channel transitions to a closed
conformation from an open or inactivated state. Deactivation occurs after brief
membrane depolarizations in which the channel transitions from an open to
closed state, or when a channel transitions from an inactivated to a closed state
once a longer depolarization event has ended. This kinetic parameter has not
been studied as widely as channel activation and inactivation; however,
alterations in the selectivity filter (Talavera et al. 2003), and the I-II (Vitko et al.
2005) and III-IV linkers (Chemin et al. 2001) are associated with altered rates of
deactivation.
T-type channels deactivate more slowly than their HVA counterparts;
CaV3.3 deactivates the fastest, followed by CaV3.2 and CaV3.1. Experimentally,
deactivation is measured by stepping the voltage from holding potential to -30
mV briefly in order to activate channels without allowing them to inactivate. Cells
are then hyperpolarized to various potentials to induce tail currents. A single
exponential function in the form Aie-t/τi + C is fit to the decaying portion of the tail
currents in order to determine the rate of deactivation. Ai represents the rate
constant, t represents the time interval, τi represents the time constant, and C
represents the steady-state asymptote.
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T-type calcium channels and pain sensation
Changes in neuronal excitability in diabetes play a central role in the
development of complications. In addition to N-type channels (Zamponi et al.
2009), T-type channels (particularly CaV3.2) are crucial in pain sensation; they
are present throughout pain pathways and may contribute to both central and
peripheral sensitization to pain (Nelson et al. 2006). Studies show that mibefradil
(a preferential T-type calcium channel blocker) elicits antinociception in adult rats
(Todorovic et al. 2002) and mice (Kim et al. 2003); through these studies,
peripheral T-type calcium channels were shown to be an important mediator of
pain. Data from CaV3.2 knockout mice shows that this channel is critical for pain
perception because these mice show a decreased pain response to acute
mechanical, thermal, and chemical pain, as well as to tonic pain such as
intraperitoneal or intradermal injections of irritants (Choi et al. 2007). Similarly,
knockdown of T-type channels with anti-sense oligodeoxynucleotides produces a
long-lasting anti-nociceptive effect in healthy rats (Bourinet et al. 2005).
T-type channels are also implicated as having a major role in chronic and
neuropathic pain (Zamponi et al. 2009).

CaV3.2 upregulation contributes to

increased excitability in DRG neurons from rats with experimental diabetic
neuropathy (Jagodic et al. 2007).

Likewise, in another rat model of diabetic

neuropathy, T-type calcium channels are implicated as playing a major role in
allodynia, as treatment with ethosuximide (a T-type calcium channel blocker)
produces reversal of symptoms (Matthews et al. 2001).

Similarly, rats with
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paclitaxel-induced neuropathic pain experience a reversal of mechanical and
thermal allodynia and hyperalgesia upon treatment with ethosuximide (Flatters et
al. 2004). In rats with experimental neuropathic pain, treatment with mifebradil
blocks mechanically- and thermally-induced hyperalgesia and allodynia (Dogrul
et al. 2003). T-type VGCC knockdown with anti-sense oligodeoxynucleotides
reduces hyperalgesia in mononeuropathic rats (Bourinet et al. 2005). Similarly,
in STZ-induced diabetic rats with painful neuropathy, silencing CaV3.2 expression
with antisense oligonucleotides produces thermal and mechanical antihyperalgesic effects (Messinger et al. 2009).

The 5α-reduced neuroactive

steroid ((3β, 5α, 17β)-17-hydroxyestrane-3-carbonitrile) is specific for blocking Ttype currents and is also a potent peripheral analgesic in adult rats with
neuropathic pain (Pathirathna et al. 2005).

T-type calcium channels in diabetes
T-type channels have the unique ability to activate at voltages close to the
cell’s resting membrane potential and then inactivate rapidly; these properties
confer them the ability to finely regulate cellular excitability and initiate action
potentials and oscillatory behavior (Chemin et al. 2002). Shankarappa et. al.
2011 and others have shown that dorsal root ganglion neurons (DRG) from
diabetic rats display increased T-type calcium currents (Hall et al. 1995; Jagodic
et al. 2007; Latham et al. 2009; Messinger et al. 2009; Shankarappa et al. 2011).
Additionally, there is a depolarizing shift in steady-state inactivation of T-type
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current in these neurons, indicating increased T-type channel availability and
thus increased neuronal excitability (Jagodic et al. 2007; Shankarappa et al.
2011). In a similar study, non-diabetic rat DRG neurons exposed to diabetic
BioBreeding Worcester (BB/W) rat serum have increased VGCC current (Ristic
et al. 1998).

Increased T-type current and depolarizing shifts in availability,

consistent with increased neuronal excitability, have been clearly established
both at the cellular and behavioral levels (Jagodic et al. 2007; Latham et al. 2009;
Messinger et al. 2009).
Diabetes induces electrophysiological changes in many tissues; in culture,
increases in T-type calcium current density are seen in neonatal ventricular
cardiomyocytes and in HEK-α1H cells incubated in hyperglycemic conditions (Li et
al. 2005; Shankarappa 2010). Pancreatic β cells exposed to diabetic human
serum show increased VGCC current in vitro (Juntti-Berggren et al. 1993).
Likewise, it was shown that in hyperglycemic diabetic rats, T-type calcium current
was significantly increased in pancreatic β cells in vivo (Kato et al. 1994; Kato et
al. 1996). There are numerous mechanisms by which CaV3.2 activity could be
altered in hyperglycemic conditions; however, increased gene expression does
not appear to play a major role in DRG neurons and it is not driving channel upregulation in HEK-α1H cells, since this model system does not involve an
endogenous promoter system.
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Effects of hyperglycemia
Increased concentrations of intracellular glucose in diabetes can be
metabolized via several cellular pathways including glycolysis, the polyol
pathway, the hexosamine pathway, the protein kinase C (PKC) pathway, and the
advanced glycation end-product pathway (Figure 2) (Brownlee 2005).
In the polyol pathway, glucose is reduced to sorbitol by aldose reductase
with concurrent NADPH oxidation.

Sorbitol is then oxidized to fructose by

sorbitol dehydrogenase with NAD+ reduction; increased flux through this pathway
leads to increased oxidation of NADPH, which limits the degradation of hydrogen
peroxide.

Thus, superoxide accumulates in hyperglycemia.

Inhibition of the

polyol pathway with an aldose reductase inhibitor does not reverse the effects of
hyperglycemia on CaV3.2 calcium currents (Shankarappa 2010).
Hyperglycemia enhances PKC activity via increased diacylglycerol (DAG)
production (Xia et al. 1994; Koya et al. 1997). This enhanced PKC activity is
known to change expression of many genes. For example, enhanced PKCβ
activity in diabetic rodent kidney leads to heightened TGF-β mRNA expression
(Koya et al. 1997); PKCβ inhibition prevents increases in TGF-β, fibronectin, and
type IV collagen expression (Koya et al. 2000). Using bovine aortic epithelial
cells (BAEC), Pieper and Riazul showed that hyperglycemia induces NF-κB
activation (Pieper et al. 1997). This is a transcription factor that regulates the
expression of many genes, including proinflammatory cytokines, NOS, and
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Polyol Pathway

Hexosamine Pathway

PKC Pathway

AGE Pathway

Figure 2. Four pathways into which excess glucose can enter into in the cell.

Increased glucose concentrations can lead to increased flux through the polyol, hexosamine,
PKC, and AGE pathways. Figure is modified from (Brownlee 2005)
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regulators of immune responses. Using the same BAEC model system, Kuboki
et. al 2000 showed that PKCβ inhibition increases eNOS mRNA expression.
PKC phosphorylation regulates T-type calcium channels, but with varying
results. With PKC activation, some groups observe inhibition of T-type current in
rat sensory neurons (Schroeder et al. 1990), mouse thalamic neurons (Cheong
et al. 2008), and mouse DRG neurons (Zhang et al. 2011). On the other hand,
studies show increased T-type current with PKC activation in rat thalamic
neurons (Joksovic et al. 2010) and neonatal ventricular myocytes (Furukawa et
al. 1992), as well as in Xenopus oocytes (Park et al. 2003; Park et al. 2006) and
Chinese hamster ovary cells (Chemin et al. 2007) over-expressing T-type
channels. PKC remains a possible factor of modulation of the α1H channel and
as such, is a good candidate for future studies.
Advanced glycation end products (AGE) are created by non-enzymatic
glycosylation. This is a process by which glucose moieties are attached to amino
groups of proteins via nucleophilic attack with the formation of a Schiff base.
Over a period of weeks, the Schiff base rearranges into a stable, though
reversible, sugar-protein adduct called an Amadori product. Through a second
series of reactions, Amadori products can be converted into permanent
advanced glycosylation end-products on long-lived proteins (with a half-life of
several weeks or more) (Brownlee et al. 1984). Problems can arise when these
modified proteins are important for regulating gene expression; another
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consequence is the modification of extracellular matrix (ECM) proteins, thereby
changing communication between the ECM and cell. Modified proteins can also
diffuse out of the cell and activate AGE receptors, leading to inflammation
(Brownlee 2005). AGE contribute to many disease processes in diabetes, such
as retinopathy, blood flow abnormalities, and nephropathy (Peppa et al. 2002).
In this study, I did not explore the possibility that AGE modulate CaV3.2 function
because the development of AGE follow a much slower time-course than the
changes I studied here, which are detected in as little as 24 hours posttreatment.

N-Glycosylation
Another possible mechanism by which hyperglycemia leads to increased
CaV3.2 function is increased flux through the hexosamine pathway.

In this

pathway, the enzyme glutamine:fructose-6-phosphate amidotransferase (GFAT)
converts glutamine and excess fructose 6-phosphate from glycolysis into
glutamate and glucosamine 6-phosphate. Through another series of reactions,
glucosamine

6-phosphate

is

converted

into

uridine

diphosphate-N-

acetylglucosamine (UDPGlcNAc). UDPGlcNAc can be added to proteins via Oglycosylation or can be further converted into CMP-sialic acid (CMP-NeuNAc).
This is the active form of sialic acid that can be incorporated into oligosaccharide
chains attached to asparagine residues of proteins in a process known as Nglycosylation (Tanner 2005; Tomlinson et al. 2008).
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N-glycosylation starts on the cytosolic side of the ER, where membraneanchored dolichol pyrophosphate is enzymatically linked to two GlcNAc and five
mannose moieties. This precursor molecule is flipped into the lumen of the ER,
where four mannose and three glucose moieties are added. The glycan is then
transferred from the lipid to the protein, and all three glucose moieties and one
mannose are clipped (Figure 3) (Jaeken 2003). The process continues in the
Golgi network where the oligosaccharide chain undergoes further processing
(such as sialic acid addition) to become a high mannose-, hybrid-, or complextype oligosaccharide chain (Figure 4) (Durand et al. 2000).
CaV3.2 has four predicted glycosylation sites (Cribbs et al. 1998; Gupta et
al. 2004), some of which may be glycosylated during physiological conditions to
allow for appropriate processing and expression of the channel at the membrane
(Schmidt et al. 1985; Schmidt et al. 1986).

There is sparse information

concerning glycosylation of T-type channels; other channel types are better
characterized in terms of their modulation by N-glycosylation. For instance, after
removal of sialic acids, sodium currents from cardiac myocytes, rat skeletal
muscle sodium channels (rSkM1), rat neuronal sodium channels (rNaV1.3), and
human cardiac sodium channels (hH1a) display a depolarizing shift in steadystate activation (indicative of a decrease in channel open probability) (Bennett et
al. 1997; Zhang et al. 1999; Stocker et al. 2006; Xu et al. 2008) as well as a
depolarizing shift in the time constants of activation and inactivation kinetics
(Bennett et al. 1997). Voltage-gated potassium channels are also modulated by
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Figure 3. N-linked glycosylation pathway.

N-glycosylation begins on the cytosolic side of the ER with the synthesis of a lipid-linked precursor
molecule. Next, the precursor is flipped to the luminal side of the ER, sugar moieties are added
and trimmed, and the oligosaccharide tree is transferred to an asparagine residue of a protein.
The final processing steps occur in the Golgi apparatus, completing the N-glycosylated process.
Figure is modified from (Cartwright 2009)
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Figure 4. Types of N-linked glycosylation products.

N-linked glycosylation produces three types of oligosaccharide chains: high mannose, hybrid, and
complex types. Complex N-glycans can be bi-, tri-, or tetra-antennary. All products of N-linked
glycosylation have a common core comprised of two N-acetylglucosamine and three mannose
moieties, outlined in blue. Numbers on the sugar moieties refer to the type of glycosidic linkage.
Modified from (Cartwright 2009)
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glycosylation: removal of sialic acids from Kv2.1, Kv4.2, Kv4.3, Kv12.2, Kv3.1
and shaker K+ channels causes a depolarizing shift in voltage-dependent
activation, meaning that the channels have a decreased open probability (Brooks
et al. 2006; Johnson et al. 2008; Noma et al. 2009; Schwetz et al. 2011), as well
as slower kinetics of current activation and deactivation (Hall et al. 2011). These
results show that the presence of negatively-charged sialic acid moieties
enhances the function of voltage-sensing ion channels, either by direct
interaction or by an electrostatic effect (Recio-Pinto et al. 1990; Bennett et al.
1997; Zhang et al. 1999).
Sialic acid is negatively charged, and the simplest explanation for its
modulation of ion channels is that these charges may affect the electric field
surrounding voltage-sensitive gating elements of the channels (Bennett et al.
1997; Marban et al. 1998).

The charges may also increase local cation

concentration (Schmidt et al. 1987).

Alternatively, sialic acid residues may

influence channel stability (Recio-Pinto et al. 1990). Hyperglycosylation could
contribute to increased current density and other possible biophysical changes in
CaV3.2 during hyperglycemia by increasing sialic content and therefore, the
number of negative charges.

Gangliosides
Gangliosides are complex glycosphingolipids that contain sialic acid
(Sastry 1985); they are synthesized from ceramide, which is converted to
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glucosylceramide in the ER by UDP-glucose:ceramide β-glucosyltransferase.
Galactose and a sialic acid moiety are added to yield the ganglioside GM3, which
is the precursor to most of the complex brain gangliosides.

GM3 can be

converted into at least 14 other gangliosides with varying combinations of sialic
acid, galactose, and N-acetylgalactose moieties (Figure 5); these reactions likely
occur in the Golgi network. GM3’s conversion to other gangliosides is regulated
by five sialyltransferases and six glycosyltransferases, which are regulated by
phosphorylation and N-glycosylation (Yu et al. 2004). GM1, GD1a, GD1b, and GT1b
are the four most common gangliosides in the human nervous system (Sastry
1985; Lopez et al. 2009). GM1 has been identified as the receptor for cholera
toxin (Cuatrecasas 1973; Holmgren et al. 1973; King et al. 1973; Merritt et al.
1994).

Cholera toxin is a protein consisting of a single catalytic A subunit

responsible for entering the cell and causing toxicity, and a pentamer of B
subunits (Lonnroth et al. 1973; Sanchez et al. 2011). The B subunits specifically
bind GM1 to bring the toxin close to the membrane (Holmgren 1981; Merritt et al.
1994).

Gangliosides in the nervous system
Neuronal membranes are naturally enriched in gangliosides.

Their

expression is developmentally regulated; ganglioside concentrations change
throughout the life of an animal in various processes such as differentiation,
maturation, and aging. For example, GD3 is high during prenatal nervous system
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Figure 5. Pathways of ganglioside biosynthesis

Ganglioside biosynthesis, beginning with ceramide (Cer). The four principal gangliosides in the
nervous system are highlighted by red brackets. Sialic acid (SA); GM2/GD2/GT2-synthase
(GalNAcT); galactosyltransferase I (GalT1); GM1-synthase (GalT2); galactosyltransferase III
(GalT3); glucosyltransferase (GlcT); GM3-synthase (ST1); GD3-synthase (ST2); GT3-synthase
(ST3); GD1a-synthase (ST4); GT1a-synthase (ST5); GM4-synthase (ST6). Modified from Yu,
R.K. et. al., 2004
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development but is low after birth (Fishman et al. 1976). Ganglioside expression
is regionally specific due to the biosynthetic enzymes expressed locally. For
instance, the cerebral cortex is enriched with GD1a and GD1b but is low in GQ1b.
The molecular layer of the cerebellar cortex has high levels of GD1a, whereas the
granular layer has high levels of GD1b, GT1b, and GQ1b (Kotani et al. 1993).
Gangliosides are predominantly located in the outer leaflet of the plasma
membrane, where they partition laterally into lipid rafts (Lopez et al. 2009). The
strategic localization of gangliosides in these microdomains enriched with
cholesterol, other sphingolipids, and various signaling complexes allows them to
function in molecular recognition and interact with many other molecules. Thus,
they serve many important functions in neuronal membranes. A few of their
known functions include regulation of cell morphology (Simmons et al. 1975),
binding and release of neurotransmitters, regulation of the cell cycle (Misasi et al.
1997) and membrane receptor functionality for many compounds including
cholera toxin, tetanus toxin (van Heyningen 1959), botulinum toxin (Simpson et
al. 1971; Simpson et al. 1971), and rotaviruses (Hu et al.; Banda et al. 2009;
Haselhorst et al. 2009). Additionally, they are known to regulate the function of
signaling proteins including insulin, epidermal growth factor, and vascular
endothelial growth factor receptors (Lopez et al. 2009).
Since ganglioside expression is tightly regulated both by region and
developmental stage, alterations of the concentration of specific gangliosides are
associated with varying disease processes.

Gangliosidoses, also known as
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ganglioside storage disorders, occur due to decreased breakdown and
subsequent accumulation of specific gangliosides in the lysosome. Two known
forms include GM1 and GM2 gangliosidoses.
GM1 gangliosidoses occur as a result of mutations of the GLB1 gene
encoding β-galactosidase, an enzyme that cleaves terminal β-galactosyl moieties
from GM1 and glycoproteins. The disease is separated into three types based on
clinical onset of symptoms. Type one is infantile-onset (<7 months of age), with
quickly progressing neurodegeneration and death by one to two years of age. In
type two (juvenile onset – seven months to three years of age), neurological
symptoms such as ataxia, seizures, and dementia progress more slowly but are
eventually lethal.

Type three is adult onset and is chronic.

This form is

characterized by progressive motor dysfunction due to lysosomal deposits in the
caudate nucleus (Brunetti-Pierri et al. 2008).
GM2 gangliosidoses include Tay-Sachs disease, Sandhoff’s disease, and
an AB-variant form of the disease. All three of these diseases are characterized
by progressive motor deterioration typically leading to a vegetative state before
the age of four. β-hexosaminidase is an exo-glycosidase that cleaves terminal
GlcNAc and GalNAc moieties from gangliosides and glycoproteins. This enzyme
requires a cofactor known as the GM2 activator protein.

Tay-Sach’s and

Sandhoff’s are caused by mutations to the HEXA or HEXB genes, which encode
the α or β subunit of β-hexosaminidase, respectively. The AB-variant form is
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caused by mutation to the GM2A gene encoding the GM2 activator protein
(Mahuran 1999).
Altered ganglioside concentration is also implicated in cancer (Fredman
1994).

As an example, a study by Traylor and Hogan shows that 24 of 25

patients with grade IV astrocytoma have a decrease in the total level of
gangliosides with an increased proportion of the ganglioside GD3 (Traylor et al.
1980).

Altered glycolipid concentrations in tumors may be important for

metastasis due to decreased cell-matrix or cell-cell adhesion (Rosner 1993).
Overall ganglioside levels are also decreased in Creutzfeld-Jakob disease
(Korey et al. 1961), with an increase in the proportion of GD3, and a decreased
proportion of GM1, GD1a, GD1b , and GT1b (Ohtani et al. 1996).
Antibodies to gangliosides have been described in numerous disorders
affecting the nervous system such as Guillain-Barré Syndrome (Kaida et al.
2009), Multiple Sclerosis (Sadatipour et al. 1998; Mata et al. 1999; Marconi et al.
2006), Amyotrophic Lateral Sclerosis (Sanders et al. 1993; Mizutani et al. 2003;
Yamazaki et al. 2008), Alzheimer’s Disease (Chapman et al. 1988; Schott et al.
1996; Hatzifilippou et al. 2008), Lupus (Greenwood et al. 2002), AIDS (Witkin et
al. 1983; Sorice et al. 1995), and Hashimoto’s and Graves’ disease (Sawada et
al. 1980). Clearly, strict regulation of ganglioside concentrations is crucial for
proper neuronal function.

34
Gangliosides in diabetes
In diabetes, there is an alteration in the concentrations of brain glycolipids,
and the presence of antibodies against various gangliosides has been detected
as part of the autoimmune response of diabetes; autoantibodies to gangliosides
GM1, GM2, GM3, GD1a, GD1b, GD3, GT1b, GT3, and a novel ganglioside GM2-1 are
present in the serum of diabetic patients (Lucchetta et al.; Gillard et al. 1989;
Tiberti et al. 1995; Dotta et al. 1996 Sep; Dotta et al. 1997; Matà et al. 2004).
In 1993, Kumar and Menon reported a decrease in gangliosides in brain
samples from diabetic rats; insulin treatment of these rats restored normal
glycolipid levels (Kumar et al. 1993). Ganglioside treatment is also beneficial in
diabetic neuropathy (Norido et al. 1984; Calcutt et al. 1988; Eichberg et al. 1993).
When cultured in hyperglycemic conditions, HEK-293 cells contain a
negligible amount of GM1 (Cho et al. 2010). Therefore, we hypothesize that in
hyperglycemic

conditions,

altered

membrane

ganglioside

composition

–

specifically a decrease in membrane GM1 – affects the properties and function of
proteins in neuronal membranes, including CaV3.2; I tested this possibility in aim
two of this study.

Gangliosides and calcium homeostasis
Several lines of evidence suggest a role for GM1 on calcium homeostasis.
Pre-treatment with GM1 prevents glutamate-, kainate-, and TOPA- (2,4,5trihydroxyphenylalanine, an AMPA receptor agonist) induced neurotoxicity in rat
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hippocampal and cerebellar granular neurons (Favaron et al. 1988 Oct; Manev et
al. 1990; Skaper et al. 1991; Skaper et al. 1992).

Similarly, GM1 treatment

reduces EAA-induced neurotoxicity in chicken retinal neurons (Facci et al. 1990).
In another study, rat cerebellar granule neurons incubated in GM1 were
significantly more viable and did not experience the normal increase in ROS and
NO formation elicited by neurotoxic levels of glutamate (Avrova et al. 1998). GM1
is postulated to prevent the protracted elevation in intracellular calcium that
occurs after exposure to high levels of NMDA, AMPA or kainate receptor
agonists, such as glutamate (de Erausquin et al. 1990; Costa et al. 1993;
Hoffman et al. 1995 Jun). Bachis et. al. postulated that GM1’s neuroprotective
effect may be mediated by TrkB (a tyrosine receptor kinase whose endogenous
ligand is brain-derived neurotrophic factor, BDNF) (Bachis et al. 2002).
Other evidence for GM1 affecting calcium homeostasis exists as well;
Guérold et. al. showed that GM1 decreases calcium influx in primary cultures of
chick brain (Guérold et al. 1992). Other reports show that binding of CtxB to GM1
increases intracellular calcium levels in sensory neurons (Milani et al. 1992),
fibroblasts (Spiegel et al. 1988; Buckley et al. 1995), and T-lymphocytes (Dixon
et al. 1987; Gouy et al. 1994); the increase in intracellular calcium is inhibited
when extracellular calcium was removed, indicating that the effects of GM1 and
CtxB are due to modulation of calcium channels in the plasma membrane, as
opposed to release from an internal store. In neuroblastoma cells, 200 nm GM1 is
reported to inhibit L-type calcium channels with complete inhibition occurring with
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2 µM GM1 treatment. CtxB addition and the subsequent binding to its target, GM1,
releases the inhibitory effect (Carlson et al. 1994). In contrast, when used at
higher concentrations such as 10 or 100 µM, GM1 is reported to activate L-type
calcium channels in PC12 cells (Hilbush et al. 1992).

In cultured cerebellar

granule neurons, both negative and positive regulation of calcium currents is
reported: GM1 appears to serve as an intrinsic inhibitor of L-type channels during
the first week in vitro, and then as an intrinsic activator of calcium conductance
(including L-type) afterwards (Wu et al. 1996). Addition of antibodies against GM1
in Neuro2a cells activates an amiloride-sensitive calcium entry pathway, likely Ttype calcium channels, although this possibility was not specifically tested
(Ravichandra et al. 1999). In addition to these direct effects, GM1 is known to
regulate excitatory opioid receptor-mediated hyperalgesia by second messenger
modulation of potassium and calcium channels (Crain et al. 1990). Ganglioside
composition clearly modulates ion channels; therefore I explored the role of the
gangioside GM1 on the α1H T-type calcium channel in this thesis.

CHAPTER TWO
MATERIALS AND METHODS
Cell culture
Human embryonic kidney (HEK 293) cells stably transfected with CaV3.2
cDNA (HEK-α1H) (Lee et al. 1999) were grown in a high glucose concentration
(25 mM glucose) or normal glucose concentration (5.6 mM glucose) Dulbecco’s
minimum essential medium (ThermoFisher, Waltham, MA) supplemented with
10% fetal bovine serum, 100 I.U. penicillin, 100 µg/mL streptomycin, and 1
mg/mL G418 sulfate (Mediatech, Manassas, VA). Cells were incubated at 37
degrees in a 5% CO2:95% air humidified atmosphere. For electrophysiology and
confocal imaging, cells were plated at low density (<10% confluency) on 12 mm
round coverslips (Carolina Biological Supply, Burlington, NC). Cells were used
for 50 passages after transfection.

Electrophysiology
Currents were recorded using whole-cell patch clamping technique at
room temperature. Data were acquired and digitized using an Axopatch 200B
Amplifier and Digidata 1332A analog to digital converter (Molecular Devices,
Sunnyvale, CA).

Currents were recorded in an external solution containing 5
37
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mM CaCl2, 140 mM TEACl, 10 mM HEPES, and 10 mM glucose (Sigma-Aldrich,
St. Louis, MO), at pH 7.4 and 300 mOsm/kg. Pipettes were fabricated from thin
wall borosilicate glass capillary tubes (Warner Instruments, Hamden, CT) using a
flaming/brown micropipette puller (Sutter Instrument, Novato, CA). Pipettes had
a resistance of 2-5 MΩ when filled with intracellular solution consisting of 108
mM CsMeS03, 4 mM MgCl2, 1 mM Cs-EGTA, 9 mM HEPES, 5 mM ATP-Mg, 10
mM GTP-Li and 15 mM phosphocreatine-TRIS (Sigma-Aldrich, St. Louis, MO), at
pH 7.3 and 300 mOsm/kg. Cell capacitance was measured by evoking transient
currents with a 10 mV depolarizing pulse from a holding potential of -90 mV.
Cells with a series resistance (RS) <10 MΩ were used; RS was compensated on
line (>80%).

To elicit currents for current-voltage relationships, cells were

depolarized for 240 ms from a holding potential of -100 mV to test potentials of
-70 mV to +40 mV in 5 mV increments.

Current activation kinetics
Current activation time constants (τon) were measured by depolarizing
cells from a holding potential of -90 mV to test potentials of -70 mV to +30 mV in
10 mV increments for 20 ms; the negative-going portion of the curve was fit to a
standard exponential function in the form Aie-t/τi + C in which Ai represents the
rate constant, t represents the time interval, τi represents the time constant, and
C represents the steady-state asymptote.
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Current inactivation kinetics
Current inactivation time constants (τoff) were measured by depolarizing
cells from a holding potential of -90 mV to test potentials of -50 mV to +40 mV in
10 mV increments for 400 ms. The decaying phase of the current was fit to an
exponential function as above.

Current deactivation kinetics
Time constants of current deactivation (τdeac) were measured by
depolarizing cells from a holding potential of -90 mV to a pre-pulse potential of
-30 mV for 12 ms and then to a test potential of -30 mV to -140 mV for 15 ms to
elicit tail currents.

The decaying phase of the tail currents was fit to an

exponential function as above.

Steady-state activation and inactivation
Steady-state activation was assessed by measuring peak current evoked
by depolarization from a holding potential of -90 mV to test potentials of -90 mV
to 0 mV in 10 mV increments for 12 ms and then repolarization to -100 mV. Tail
currents at each voltage were normalized to the peak current elicited, plotted,
and fit by a single Boltzmann equation in the form of m+IMAX/{1+e^[(V50-V)/k]}
in which m is the baseline, Imax is maximal current, V50 is half-maximal activation
voltage, and k is the slope factor. To assess steady-state inactivation, cells were
depolarized from a holding potential of -90 mV to pre-pulse potentials of -110 mV
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to 0 mV for 1.5 s, returned to holding potential for 20 ms, and depolarized to -30
mV for 150 ms. Peak current from each trace was measured and normalized to
maximum current elicited. Data was plotted and fit to a Boltzmann equation as
above.

Pharmacological Analysis
The effects of addition of GM1 (1 µM; Carbosynth Ltd., Berkshire, UK),
GD1A (1 µM), CtxB (5 µg/mL), or NANA (1 µM; Sigma-Aldrich, St. Louis, MO;
Figure 6) on α1H T-type currents were assessed by measuring the changes in
current amplitude over the course of a compound’s addition.

Cells were

depolarized from a holding potential of -100 mV to a test potential of -25 mV for
100 ms every three seconds.

Control traces were obtained for at least one

minute prior to the addition of a drug; the tested compound was added over the
course of a minute and its effects on current density were recorded for at least 10
minutes.

Neuraminidase experiments
Neuraminidase (type VI, Sigma-Aldrich, St. Louis, MO) was dissolved in
PBS + 0.2% BSA at a concentration of 0.5 mg/mL (3.7 units/mL).

Before

incubation with HEK-α1H cells, this solution was diluted 1:5 in normal or high
glucose medium, giving a final activity of 0.74 units/mL. Cells were incubated for
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Figure 6. N-Acetylneuraminic acid structure.

N-acetylneuraminic acid (NANA) is the most abundant sialic acid (SA) present in the nervous
system. As such, the terms NANA and SA are used interchangeably.
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15 or 30 minutes at room temperature. After incubation, cells were washed for
five minutes in fresh medium and promptly used for electrophysiological
measurements.

Confocal imaging
After being plated on glass coverslips, HEK-α1H cells cultured in normal
glucose medium were fixed with 4% PFA and labeled overnight with a 1:200
dilution

of

anti-α1H

rabbit

polyclonal

primary

antibodies

(Santa

Cruz

Biotechnology, Inc., Santa Cruz, CA). They then were treated with Alexa-594conjugated goat anti-rabbit secondary antibodies (Molecular Probes, Eugene,
OR) at a 1:1000 dilution and 0.25 µg/mL FITC-conjugated CtxB (Sigma-Aldrich,
St. Louis, MO) for one hour. Using a Bio-Rad confocal microscope (Hercules,
CA), Z-stack images were taken. Z-stacks consisted of 10 slices, each 0.4 mm
apart with a maximum intensity projection, and were analyzed with ImageJ
Freeware (NIH) to determine colocalization.

Statistical analysis
Results are presented as mean ± SEM.

Statistical significance was

determined by Student’s t-test or one-way ANOVA with post-hoc Tukey’s test. A
p-value of <0.05 is considered significant.

CHAPTER THREE
DETERMINATION OF HYPERGLYCEMIA-INDUCED ALTERATIONS TO
CaV3.2 CHANNEL FUNCTION
Abstract
Diabetes affects approximately 8% of the American population; over 60%
of these patients experience neurological complications, such as distal symmetric
neuropathy (CDC 2011).

Rodent models of diabetic neuropathy show that

sensory neurons have heightened excitability and increased α1H T-type calcium
channel function (Hall et al. 1995; Jagodic et al. 2007; Latham et al. 2009;
Messinger et al. 2009; Shankarappa et al. 2011).
Various voltage-gated ion channels can be modulated by N-glycosylation,
by the addition of the negatively-charged sugar moiety, N-acetylneuraminic acid
(NANA) to the ion channel protein, which results in modified ion channel function
(Bennett et al. 1997; Zhang et al. 1999; Brooks et al. 2006; Stocker et al. 2006;
Johnson et al. 2008; Xu et al. 2008; Noma et al. 2009; Hall et al. 2011; Schwetz
et al. 2011).

During hyperglycemia, excess glucose present in the body is

converted into various other compounds, including sugar moieties such as
NANA.
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We hypothesize that NANA incorporation into the CaV3.2 α1H channel via
N-gycosylation (or into gangliosides during their biosynthesis) occurs during
hyperglycemia. Excess negative charges located near the mouth of the channel
pore may then alter its function directly; alternatively they could act indirectly by
changing the nearby electrical field sensed by the channel or by increasing local
cation concentrations (Recio-Pinto et al. 1990; Bennett et al. 1997; Zhang et al.
1999). The objective of this aim was to determine the effect of these excess
moieties on α1H T-type calcium channel function.
We used HEK-293 cells stably expressing the α1H T-type calcium channel.
Cells were grown in either normal (100 mg/dL) or high (450 mg/dL) D-glucose
medium for at least 24 hours. To test if the presence of sialic acids alters T-type
channel function, these sugar moieties were enzymatically cleaved by treatment
with 0.8 units of type VI neuraminidase (Neu) for 15 or 30 minutes at room
temperature before assaying for calcium channel function with whole cell voltage
clamp electrophysiology.

In all conditions, current density, current-voltage

relationships, current kinetics, and steady-state properties were assayed.
Overall, cells cultured in hyperglycemic conditions depicted increased
current density, faster inactivation kinetics and increased open probability.
Fifteen minutes of Neu treatment reversed the increased current density and
accelerated inactivation kinetics. Thirty minute treatment decreased the current
density and slowed inactivation kinetics further, and reversed the increase in
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open probability. In addition, Neu treatment decreased the availability of the
channels, shifting the steady-state inactivation curve to the left. Neu treatment of
cells

cultured

in

normal

electrophysiological property.

glucose

medium

had

no

effect

on

any

Direct addition of NANA had no effect on any

property of cells cultured in either type of medium, demonstrating that the
location of these moieties and their associated negative charges must be
specific.
These results show that the α1H T-type calcium channel is modulated by
the presence of sialic acid moieties. Additionally, they suggest that there are
multiple changes occurring in hyperglycemia. We propose that both the channel
glycosylation status and the composition of the membrane alter α1H channel
function in hyperglycemic conditions.

Introduction
Neurons cultured from dorsal root ganglia (DRG) from diabetic animals
have increased T-type current density when compared to euglycemic animals
(Jagodic et al. 2007; Latham et al. 2009; Messinger et al. 2009; Shankarappa et
al. 2011).

Our lab and others have shown that this increased function also

occurs in vitro (Li et al. 2005; Shankarappa 2010). As discussed in chapter one,
many changes occur within cells during hyperglycemia and diabetes such as
altered flux through intracellular signaling pathways and altered membrane lipid
composition.

Pathways that create and/or modify glycoproteins appear to
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change as well. Forty percent of glycosylated proteins in mammalian brain have
one or more sialic acid moieties on their non-reducing terminus (Zamze et al.
1998). Hyperglycemia-induced increases in CaV3.2 sialylation could presumably
alter the mechanism by which it functions, given that sialic acid moieties are
highly negatively charged. Residues important for calcium channel gating are
located in the S4 transmembrane segments of all four domains.

These

structures contain a signature motif in which positively-charged arginine residues
are located every third amino acid in a 310 helical structure across the membrane.
The electrical field surrounding this voltage sensor is important for gating
mechanisms; it is thought that local surface charges surrounding and associating
with the channel can contribute significantly to the electrical field sensed (Bennett
et al. 1997). Increasing the number of NANA moieties attached to CaV3.2 could
also attract more calcium to the channel pore, leading to changes in biophysical
properties and ion flux, as has been reported for other channel types (Bennett et
al. 1997; Zhang et al. 1999; Brooks et al. 2006; Johnson et al. 2008; Noma et al.
2009).

Fixed negative charges located on the external membrane surface

adjacent to the channel can reduce the resting transmembrane electrical field
sensed by the S4 segments; these charges could be located on the channel itself
or in its lipid microenvironment.
There are several examples in which ion channel biophysical properties
are regulated by N-glycosylation. Voltage-gated sodium and potassium channels
are well characterized in terms of their modulation by N-glycosylation. Alpha
subunits of sodium channels from rat brain neurons were shown to be highly
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glycosylated, and these glycans contained sialic moieties (Schmidt et al. 1987;
James et al. 1989), the function of which is likely to bestow normal folding and
function to the channel, as well as to bring cations to the mouth of the pore. In
functional studies, rat skeletal muscle sodium channels (rSkM1) display
decreased currents, a depolarizing shift in channel open probability, and slower
kinetics of activation and inactivation after removal of sialic acids with
neuraminidase, mutation of glycosylation sites, or when the channels were
expressed in a sialic acid-deficient cells line (Bennett et al. 1997). Similarly,
human cardiac (hH1a) or skeletal muscle (µ1) sodium channels depicted a
depolarizing shift in steady-state activation with removal of sialic acid or inhibition
of its addition. In this study, there was also a shift in steady-state inactivation,
but this was dependent on channel type (hH1a showed a depolarizing shift, µ1
showed a hyperpolarizing one), leading the authors to conclude that sialic acids
affect channel properties via surface charges (Zhang et al. 1999). Likewise, in a
study that looked at sodium currents in cardiac myocytes, neonatal atrial
myocytes and adult atrial and ventricular myocytes showed a depolarizing shift in
channel open probability and availability and slower inactivation kinetics after
neuraminidase treatment, but neonatal ventricular myocytes did not. The authors
concluded that the “glycosylation signature” of the channel is crucial for gating
properties (Stocker et al. 2006).
Voltage-gated potassium channels are also modulated by glycosylation.
KV3.1 from rat brain is glycosylated; channels from glycosylation mutants show a
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depolarizing shift in open probability and slower inactivation kinetics (Brooks et
al. 2006).

In a similar study, glycosylation-deficient channels expressed in

neuroblastoma cells show decreased current and slower kinetics of activation,
inactivation, and deactivation, with no effects on steady-state properties (Hall et
al. 2011). These discrepancies may be due to the expression system or the
specific mutations induced.
Likewise, shaker potassium channels expressed in a sialylation-deficient
cell line display a depolarizing shift in open probability and availability, as well as
slower activation and inactivation kinetics.

In the same study, the authors

created a full glycosylation deficient channel that displayed the slower current
kinetics without the shifts in open probability and availability, suggesting that
there is both a charge effect from the sialic acids that affects steady-state
properties, as well as a modulatory effect from the other sugars in the glycan that
affect gating properties (Johnson et al. 2008). In contrast, KV12.2 channels show
a depolarizing shift in open probability with removal of N-glycans; they did not
see this effect by simply removing sialic acids, meaning that the shift was chargeindependent (Noma et al. 2009).
Studies on calcium channel de-sialylation show variable results. Removal
of sialic acids enhances T-type calcium currents in guinea pig ventricular
myocytes (Yee et al. 1989). In a study using myocytes from rabbit sinoatrial
node, neuraminidase treatment resulted in increased T-type current in five of
nine cells and decreased current in the other four. The cells with increased
current also displayed a hyperpolarizing shift in channel open probability,
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consistent with the increased current (Fermini et al. 1991). In contrast, CaV3.1
and 3.2 expressed in HEK-293 cells display decreased current, slower activation
and inactivation kinetics, and a depolarizing shift in channel availability after desialylation.

Similarly, T-type current from DRG neurons is decreased and

activation and inactivation kinetics are slower after removal of sialic acids
(Salajegheh et al. Nov 14 ,2010). Clearly, sialic acid levels are important in
determining functional properties of ion channels, whether they act through
surface charges or through a charge-independent effect.
The objective of this aim was to test the hypothesis that increased
glycosylation in hyperglycemia has a direct role in enhancing CaV3.2 current
density. To test this hypothesis, I assessed the overall levels of protein and/or
lipid glycosylation by cleaving sialic acid moieties with neuraminidase prior to
testing the electrophysiological properties of the channel.
Through this study, we determined that our model of diabetic
hyperglycemia responds in a similar manner to in vivo models in terms of
enhanced current density, and that the effects of hyperglycemia can be reversed
with removal of sialic acids. Overall, our data suggest that increased sialic acids
present on the channel itself or lipids in its direct vicinity directly alter CaV3.2
current

density,

inactivation

kinetics,

and

channel

open

probability

in

hyperglycemia, and removal of these sialic acids results in reversal of the
changes.
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Materials and Methods
HEK-293 cells stably transfected with α1H calcium channels were used in
this study. This in vitro model is ideal to assess direct changes occurring to
CaV3.2 in isolation from other cellular components that may increase the
complexity of the data and/or confound its interpretation. Cells were cultured in
normal glucose (NG) medium or high glucose (HG) medium for at least 24 hours.
NG medium contains 5.6 mM glucose, a similar level to that found in euglycemic
rats and humans. HG medium contains 25 mM glucose. Our lab and others
have measured that diabetic rats have ~27 mM blood glucose (Shankarappa
2010), and the American Diabetes Association reports that a fasting blood
glucose level higher than 126 mg/dL (~7 mM) is considered diabetic in humans.
Thus my experimental conditions represent blood glucose levels for both normal
euglycemic and diabetic hyperglycemic rats and humans.
To assay for electrophysiological properties, I used whole-cell voltage
clamp to measure current density, current-voltage relationships, kinetic
properties including time constants of current activation, inactivation, and
deactivation, and properties of steady-state activation and inactivation of CaV3.2.
In this chapter, I tested for differences in CaV3.2 calcium currents from
cells incubated in NG or HG medium. After de-sialylation with neuraminidase, I
assayed calcium currents to assess whether glycosylation alters channel function
during hyperglycemia. For these experiments, I incubated hyper- or eu-glycemic
cells at room temperature for 15 or 30 minutes with 0.8 units of type VI
neuraminidase per coverslip. One unit is defined as the enzyme activity required
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to liberate 1 µmol of NANA at α2-3, α 2-6 and α 2-8 bonds per minute at pH 5.0
and 37ºC. As a control, I added 1 µM NANA to cells cultured in HGM or NGM
during electrophysiology to test if globally increased negative charges were
responsible for the alterations in CaV3.2 channel function.

Results
Hyperglycemia increases CaV3.2 current density in vitro
I first set out to confirm the finding that incubation in hyperglycemic
conditions statistically increases CaV3.2 T-type current density in a HEK-293 cell
model (Li et al. 2005; Jagodic et al. 2007; Latham et al. 2009; Messinger et al.
2009; Shankarappa 2010; Shankarappa et al. 2011). Cells incubated in NGM
exhibited a peak CaV3.2 calcium current density of -9.47 ± 0.55 pA/pF (n=44). In
contrast, cells incubated in HGM exhibited a significantly higher peak CaV3.2
calcium current density of -16.39 ± 0.85 (n=46; p<0.001; Figure 7), a 58%
increase. Thus, we reproduced the reported increase in CaV3.2 calcium current
density in our experimental conditions.

Hyperglycemia-associated alterations of CaV3.2 kinetic properties
Next, I determined the biophysical changes to CaV3.2 resulting from
hyperglycemia. α1H T-type calcium currents inactivated significantly faster (τoff)
when cultured in high glucose medium compared to normal-glucose medium, as
seen in Figure 8; for instance when depolarized to -20 mV, cells cultured in NGM
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Figure 7: Hyperglycemia enhanced T-type calcium current in HEK-α
α1H cells.

(A) Protocol and representative calcium current traces evoked from a 240 ms depolarizing pulse
from VH= -100 mV to VT= -25 mV from cells incubated in NGM (5.6 mM) or HGM (25 mM). (B) IV relationships from HEK-α1H cells cultured in NGM (open circles; n=44) or HGM (closed circles;
n=46). (C) Bar graph comparing peak current densities from B. Data shown in B and C are
means ± SEM. *p< 0.001, unpaired Student's t-test.
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Figure 8. Hyperglycemia was associated with faster inactivation kinetics of CaV3.2
channels.

(A) Protocol and representative calcium current trace evoked by a 400 ms depolarizing pulse
from VH= -90 to VT= -20 mV from HEK-α1H cells. (B) τoff values from cells cultured in NGM (open
circles; n=43) or HGM (closed circles; n=46). Data shown are mean ± SEM. *p< 0.05, unpaired
Student's t-test. In some cases, error bars are smaller than symbol size.
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displayed a τoff value of 28.60 ± 1.08 ms (n=43), whereas cells incubated in HGM
displayed a τoff value of 23.39 ± 1.00 ms, (n=46; p<0.05; see also Table 2). On
the other hand, neither the rate of activation (τon; at -30 mV: NG: 9.76 ± 0.77 ms,
n=43; HG: 8.90 ± 1.15 ms, n=46; p=0.542; Table 3) nor the rate of deactivation
(τdeac; at -90 mV: NG: 4.72 ± 0.36 ms, n=42; HG: 4.45 ± 0.33 ms, n=46; p=0.582;
Table 4) were altered with hyperglycemic culture conditions.

Hyperglycemia-associated alterations of CaV3.2 steady-state properties
The average steady-state activation V50 value from HEK-α1H cells
incubated in high glucose medium was significantly shifted 4 mV leftward (-31.60
± 0.83 mV; n=45) compared to cells incubated in normal glucose medium (-27.39
± 0.79 mV; n=43; p<0.001). This shift indicates that CaV3.2 channels from cells
incubated in high glucose medium have a higher probability of opening when the
cell is depolarized (Figure 9).

On the other hand, CaV3.2 steady-state

inactivation V50 values from cells incubated in high glucose medium (-54.21 ±
0.65 mV; n=46) were statistically indistinguishable from cells incubated in normal
glucose medium (-53.72 ± 0.68 mV; n=43; P=0.604), indicating that there is no
change in the channel’s availability in hyperglycemia (Figure 10).
Overall, these data corroborate other reports that demonstrate increased
current density and changes to the open probability of α1H T-type calcium
channels when subjected to hyperglycemic conditions.

To assess whether
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τoff (ms)
V
(mV)

NG

n

HG

n

p

-40

84.26 ± 8.03

42

69.06 ± 8.05

44

0.185

-30

37.35 ± 1.49

43

30.40 ± 1.52*

46

0.002

-20

28.60 ± 1.08

43

23.39 ± 1.00*

46

<0.001

-10

24.19 ± 0.82

43

20.15 ± 0.75*

46

<0.001

0

21.64 ± 0.65

43

18.46 ± 0.58*

46

<0.001

10

20.17 ± 0.60

43

17.55 ± 0.48*

46

<0.001

20

19.39 ± 0.52

43

17.26 ± 0.47*

41

0.003

30

22.09 ± 1.21

41

19.91 ± 1.63

41

0.286

40

33.93 ± 3.05

33

28.10 ± 3.42

38

0.213

Table 2. Hyperglycemia was associated with faster inactivation kinetics of CaV3.2
channels.

P-values are from unpaired Student's t-test comparing NG and HG values at each given
voltage.
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τon (ms)
V
(mV)

NG

HG

p

-40

15.07 ± 1.10 15.38 ± 2.26

0.905

-30

9.76 ± 0.77

8.90 ± 1.15

0.542

-20

5.84 ± 0.36

4.71 ± 0.60

0.116

-10

3.68 ± 0.20

2.97 ± 0.33

0.074

0

2.45 ± 0.12

2.14 ± 0.12

0.071

10

1.85 ± 0.11

1.76 ± 0.20

0.700

20

1.54 ± 0.12

1.66 ± 0.42

0.790

30

1.52 ± 0.21

1.80 ± 0.64

0.687

Table 3. Activation rate constants from HEK-α
α1H cells incubated in normal or high glucose
medium.

NGM (n=43), HGM (n=46); observed differences were not statistically significant (p>0.05;
unpaired Student's t-test).
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τdeac (ms)
V
(mV)

NG

HG

p

-60

5.10 ± 0.59 5.16 ± 0.53

0.940

-70

4.92 ± 0.42 5.42 ± 0.56

0.479

-80

4.58 ± 0.45 5.26 ± 0.53

0.334

-90

4.72 ± 0.36 4.45 ± 0.33

0.582

-100

3.92 ± 0.27 4.29 ± 0.34

0.402

-110

3.68 ± 0.28 3.34 ± 0.22

0.338

-120

3.35 ± 0.27 3.38 ± 0.28

0.939

-130

3.52 ± 0.33 3.61 ± 0.40

0.863

-140

3.45 ± 0.24 3.42 ± 0.64

0.964

Table 4. Deactivation rate constants from HEK-α
α1H cells incubated in normal or high
glucose medium.

NGM (n=42), HGM (n=46); observed differences were not statistically significant (p>0.05;
unpaired Student's t-test).
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Figure 9. Hyperglycemia increased CaV3.2 channel open probability.

(A) Protocol and representative calcium tail current evoked by a 12 ms depolarizing pulse from
VH= -90 mV to VP= -90 to 0 mV, followed by hyperpolarization to VT= -100 mV in HEK-α1H cells.
(B) Steady state activation curves obtained from cells cultured in NGM (open circles; n=43) or
HGM (closed circles; n=45). (C) Bar graph comparing V50 values from curves in B. Data shown
in B and C are mean ± SEM. *p< 0.001 (unpaired Student's t-test). Error bars are smaller than
symbol size.
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Figure 10. Steady-state inactivation (SSI) V50 values from HEK-α
α1H cells incubated in
normal or high glucose medium.

(A) Protocol and representative calcium current traces evoked from a 1.5 s depolarizing pulse
from VH= -90 mV to VP= -110 mV to 0 mV, a 20 ms return to VH, then a 150 ms depolarizing pulse
to VT= -30 mV. (B) SSI curves obtained from cells cultured in NGM (open circles; n=43) or HGM
(closed circles; n=46). Data are means ± SEM.

Observed differences were not statistically

significant (unpaired Student's t-test). In some cases, error bars are smaller than symbols.

increased

sialylation

occurs

under

hyperglycemic

conditions,

I
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used

neuraminidase to remove sialic acid moieties from the external side of the cells.

Effect of de-sialylation on CaV3.2 channel properties
I cleaved sialic acid moieties from HEK-α1H cells incubated in normal or
high glucose medium using type VI neuraminidase. CaV3.2 T-type currents from
cells cultured in hyperglycemic conditions exhibited significantly decreased
current density after a 15-minute (-7.30 ± 0.63 pA/pF; n=4) or 30-minute (-5.62 ±
0.39 pA/pF; n=19) incubation with neuraminidase compared to control conditions
(-17.21 ± 1.13 pA/pF; n=26; p<0.001; Figures 11 and 12).
Analysis of the biophysical properties of α1H showed that τon (at -30 mV:
HG: 8.49 ± 0.71 ms, n=26; +15 Neu: 7.07 ± 0.56 ms, n=4; +30Neu: 7.77 ± 0.45
ms, n=19; p>0.05; Table 5) and τdeac values (at -90 mV: HG: 4.11 ± 0.34 ms,
n=26; +15Neu: 3.52 ± 0.44 ms, n=4; +30 Neu: 4.44 ± 0.55 ms, n=19; p>0.05;
Table 6) were indistinguishable between groups. As previously described, α1H
currents from cells cultured in HGM exhibited a faster rate of inactivation
compared to cells cultured in NGM.

A 15-minute neuraminidase treatment

reversed τoff values such that they were no longer significantly faster than cells
cultured in NGM. In contrast, cells cultured in HGM that were treated for 30
minutes with neuraminidase exhibited τoff values that were significantly slower
than cells cultured in NGM (at -20 mV: NG: 29.34 ± 1.12 ms, n=25; HG: 22.40 ±
1.03 ms, n=26; HG+15Neu: 25.00 ± 1.01 ms, n=4; HG+30Neu: 34.27 ± 1.55 ms,
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Figure 11. Treatment with neuraminidase decreased CaV3.2 calcium current density in
HEK-α
α1H cells cultured in high glucose medium.

(A) Protocol and representative calcium current traces evoked from a 240 ms depolarizing pulse
from VH= -100 mV to V = -25 mV from cells incubated in NGM (5.6 mM) or HGM (25 mM). (B) I-V
relationships from cells cultured in NGM (open circles; n=25) or HGM (closed circles; n=26). (C)
I-V relationships from cells cultured in NGM, HGM, or HGM with a 15- (blue; n=4) or 30-minute
(pink; n=19) Neu incubation. NG and HG symbols and error bars are removed for visual clarity.
Data shown in B and C are means ± SEM.
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Figure 12: Treatment with neuraminidase decreased CaV3.2 calcium current density and
shifts the current-voltage relationship of HEK-α
α1H cells cultured in high glucose medium.

(A) Bar graph comparing peak current from figure 11B and C. (B) I-V relationships of α1H T-type
currents from cells cultured in NGM, HGM, and HGM with a 15- or 30-minute Neu incubation, all
normalized to their own peak. A shift in the I-V curve is indicative of a shift in steady-state
properties. Data shown in A is mean ± SEM. *p< 0.04 compared to NG data, one-way ANOVA.
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τon (ms)
V
(mV)
-40
-30
-20
-10
0
10
20
30

NG

HG

14.38
± 0.97
9.31
± 1.01
4.89
± 0.20
3.33
± 0.20
2.14
± 0.09
1.63
± 0.10
1.42
± 0.16
1.51
± 0.33

14.84
± 2.10
8.49
± 0.71
5.18
± 0.32
3.15
± 0.21
2.11
± 0.13
1.43
± 0.10
1.10
± 0.10
1.00
± 0.12

HG
+15 Neu
8.94
± 0.54
7.07
± 0.56
3.88
± 0.38
2.54
± 0.26
1.73
± 0.05
1.26
± 0.05
1.17
± 0.09
1.21
± 0.16

HG
+30 Neu
14.35
± 1.26
7.77
± 0.45
5.15
± 0.29
3.42
± 0.20
2.68
± 0.30
1.95
± 0.15*
1.91
± 0.27*
2.15
± 0.35*

Table 5. Effect of neuraminidase treatment on activation rate constants from cells cultured
in high glucose medium.

NG (n=25), HG (n=26), HG + 15 minutes Neu (n=4), HG + 30 minutes Neu (n=19); *p<0.05
compared to HG data, one-way ANOVA.
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τdeac (ms)

-60
-70
-80
-90
-100
-110
-120
-130
-140

NG

HG

5.01
± 0.64
5.00
± 0.54
4.51
± 0.42
4.48
± 0.43
3.85
± 0.23
3.42
± 0.40
2.95
± 0.23
3.19
± 0.39
3.38
± 0.30

4.81
± 0.61
4.30
± 0.38
4.03
± 0.44
4.11
± 0.34
3.95
± 0.34
3.17
± 0.35
3.47
± 0.49
3.86
± 0.73
3.76
± 1.17

HG
+15 Neu
5.58
± 1.90
4.44
± 1.62
3.61
± 0.33
3.52
± 0.44
3.22
± 0.46
3.41
± 0.33
2.80
± 0.38
2.84
± 0.68
2.50
± 0.51

HG
+30 Neu
5.07
± 0.31
4.12
± 0.23
4.22
± 0.61
4.44
± 0.55
3.63
± 0.21
3.43
± 0.39
2.93
± 0.17
3.89
± 1.40
4.01
± 0.98

Table 6. Effect of neuraminidase treatment on deactivation rate constants from cells
incubated in high glucose medium.

NG (n=25), HG (n=26), HG + 15 minutes Neu (n=4), HG + 30 minutes Neu (n=19); p>0.05 at all
voltages, one-way ANOVA.
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n=19; p<0.05; Figure 13 and Table 7).
Steady-state properties of α1H T-type currents from cells cultured in HGM
and treated with neuraminidase were also assayed; cells incubated in HGM
displayed a 4 mV leftward shift in steady-state activation V50 values as described
previously.

Thirty-minute, but not 15-minute incubation with neuraminidase

reverses this shift (Figure 14 and Table 8). Cells incubated in NGM and HGM
have indistinguishable steady-state inactivation V50 values; however, when cells
cultured in HGM (-55.08 ± 0.79 mV; n=26) were treated with neuraminidase for
15 (-59.69 ± 0.81 mV; n=4) or 30 minutes (-60.16 ± 0.50 mV; n=19), they
exhibited a significant leftward (hyperpolarizing) shift (p<0.04).

This shift

indicates that cells cultured in HGM have decreased channel availability after
neuraminidase treatment (Figure 15 and Table 9).
By comparison, when I cultured HEK-α1H cells in normal glucose medium
and treated them with neuraminidase for 30 minutes, current density (-8.41 ±
1.22 pA/pF; n=9) was statistically indistinguishable from untreated cells (-9.09 ±
0.61 pA/pF; n=25; p=0.590; Figure 16). Likewise, τoff, τon, and τdeac, as well as
steady-state activation and inactivation V50 values from HEK-α1H cells cultured in
NGM were unchanged by neuraminidase (Tables 10-14).

66

Figure 13. Neuraminidase treatment reversed shift in inactivation kinetics associated with
hyperglycemia.

(A) Protocol and representative calcium current trace evoked by a 400 ms depolarizing pulse
from VH= -90 to VT= -20 mV. (B) τoff values from cells cultured in NGM (open circles; n=25), HGM
(closed circles; n=26), and HGM with a 15- (blue; n=4) or 30-minute (pink; n=19) neuraminidase
incubation. Data shown are mean ± SEM. *p<0.05: HG compared to NG data; # p<0.05: HG +
30 Neu compared to NG data; φ p<0.05: HG + 30 Neu compared to all other groups (one-way
ANOVA).
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τoff (ms)
V
(mV)
-40
-30
-20
-10
0
10
20
30
40

NG

HG

71.79
± 4.87
37.51
± 1.52
29.34
± 1.12
24.78
± 0.85
22.22
± 0.68
20.70
± 0.68
19.28
± 0.66
21.95
± 1.61
33.44
± 3.88

60.04
± 5.75
28.65
± 1.50*
22.40
± 1.03*
19.45
± 0.81*
18.09
± 0.68*
17.31
± 0.59*
16.80
± 0.59*
17.17
± 1.01*
26.36
± 4.67

HG
+ 15 Neu
52.80
± 3.37
32.28
± 1.40
25.00
± 1.01
21.42
± 0.97
18.86
± 0.48
17.18
± 0.58
15.69
± 0.47
17.25
± 1.68

HG
+ 30 Neu
74.48
± 6.70
44.15
± 2.14*
34.27
± 1.55*
28.97
± 1.11*
26.13
± 1.00*
24.11
± 0.92*
26.83
± 2.50*
35.97
± 6.64*
39.67
± 8.40

Table 7. Effect of neuraminidase treatment on inactivation rate constants from cells
incubated in high glucose medium.

NG (n=25), HG (n=26), HG + 15 minutes Neu (n=4), HG + 30 minutes Neu (n=19); *p<0.05
compared to NG, unpaired Student’s t-test. Missing value is due to an n of one at this voltage.
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Figure 14. Effect of neuraminidase treatment on steady-state activation V50 values from
HEK-α
α1H cells incubated in high glucose medium.

(A) Protocol and representative calcium tail current evoked by a 12 ms depolarizing pulse from
VH= -90 mV to VP= -90 to 0 mV, followed by hyperpolarization to VT= -100 mV in HEK-α1H cells.
(B) SSA curves obtained from cells cultured in NGM (open circles; n=25), HGM (closed circles;
n=25), and HGM with a 15- (blue; n=4) or 30-minute (pink; n=19) Neu incubation. Dotted lines
represent V50 values. (C) Bar graph comparing V50 values from curves in B. Data shown in B
and C are mean ± SEM. *p< 0.04 compared to NG data (one-way ANOVA).
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Figure 15. Treatment with neuraminidase decreased CaV3.2 channel availability in HEK-α
α1H
cells cultured in high glucose medium.

(A) Protocol and representative currents evoked by a 1.5 s depolarizing pulse from VH= -90 mV to
VP= -110 to 0 mV, return to VH for 20 ms, followed by depolarization to VT= -30 mV for 150 ms.
(B) SSI curves obtained from cells cultured in NGM (open circles; n=25), HGM (closed circles;
n=26), and HGM with a 15- (blue; n=4) or 30- (pink; n=19) minute Neu incubation. Dotted lines
represent V50 values. (C) Bar graph comparing V50 values from the curves in B. Data shown in B
and C are mean ± SEM. *p<0.04 compared to either NG or HG data (one-way ANOVA).
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SSA V50
(mV)

NG

HG

HG + 15 Neu

HG + 30 Neu

-29.02
± 0.86

-33.04
± 1.02*

-34.99
± 2.00*

-30.18
± 0.70

Table 8. Effect of neuraminidase treatment on steady-state activation V50 values from cells
incubated in high glucose medium.

NG (n=25), HG (n=26), HG + 15 minutes Neu (n=4), HG + 30 minutes Neu (n=19). *p<0.02
compared to NG data (one-way ANOVA).

SSI V50
(mV)

NG

HG

HG + 15 Neu

HG + 30 Neu

-55.41
± 0.74

-55.08
± 0.79

-59.69
± 0.81*

-60.16
± 0.50*

Table 9. Effect of neuraminidase treatment on steady-state inactivation V50 values from
cells incubated in high glucose medium.

NG (n=25), HG (n=26), HG + 15 minutes Neu (n=4), HG + 30 minutes Neu (n=19). *p<0.04
compared to either NG or HG data (one-way ANOVA).
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Figure 16: Treatment with neuraminidase did not affect CaV3.2 calcium current density of
HEK-α
α1H cells cultured in normal glucose medium.

(A) Protocol and representative calcium current traces evoked from a 240 ms depolarizing pulse
from VH= -100 mV to VT= -25 mV from cells incubated in NGM (5.6 mM) or HGM (25 mM). (B) IV relationships from cells cultured in NGM (open circles; n=25) or HGM (closed circles; n=26).
(C) I-V relationships from cells cultured in NGM, HGM, or NGM with a 30-minute Neu incubation
(purple; n=9). NG and HG symbols and error bars are removed for visual clarity. Data shown in
B and C are means ± SEM.

Differences between NG with or without Neu incubation are

statistically insignificant (p=0.590; unpaired Student's t-test).
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τoff (ms)
V
(mV)

NG

NG
+ 30 Neu

p-value
(NG vs.
NG+30 Neu)

HG

p-value
(NG vs. HG)

-40

71.79 ±
4.87

60.55 ±
5.82

0.214

60.04 ±
5.75

0.125

-30

37.51 ±
1.52

32.88 ±
2.14

0.256

28.65 ±
1.50*

<0.001

-20

29.34 ±
1.12

28.55 ±
1.91

0.927

22.40 ±
1.03*

<0.001

-10

24.78 ±
0.85

23.81 ±
1.30

0.820

19.45 ±
0.81*

<0.001

0

22.22 ±
0.68

21.21 ±
1.09

0.728

18.09 ±
0.68*

<0.001

10

20.70 ±
0.68

20.12 ±
1.31

0.636

17.31 ±
0.59*

0.002

20

19.28 ±
0.66

19.14 ±
1.16

0.993

16.80 ±
0.59*

0.026

30

21.95 ±
1.61

18.98 ±
1.58

0.524

17.17 ±
1.01*

0.039

40

33.44 ±
3.88

24.13 ±
3.04

0.328

26.36 ±
4.67

0.263

Table 10. Inactivation rate constants from HEK-α
α1H cells incubated in normal glucose
medium are not affected by neuraminidase treatment.

As previously described, τoff values are significantly faster in cells cultured in HGM; NG (n=25),
NG + 30 minutes Neu (n=9), HG (n=26); (unpaired Student’s t-test).
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τon (ms)
V (mV)

NG

NG + 30 Neu

HG

-40

14.38 ± 0.97

11.78 ± 1.59

14.84 ± 2.10

-30

9.31 ± 1.01

7.27 ± 0.64

8.49 ± 0.71

-20

4.89 ± 0.20

4.56 ± 0.47

5.18 ± 0.32

-10

3.33 ± 0.16

2.58 ± 0.16

3.15 ± 0.21

0

2.14 ± 0.09

1.96 ± 0.13

2.11 ± 0.13

10

1.63 ± 0.10

1.61 ± 0.15

1.43 ± 0.10

20

1.42 ± 0.16

1.38 ± 0.18

1.10 ± 0.10

30

1.51 ± 0.33

1.33 ± 0.22

1.00 ± 0.12

Table 11. Neuraminidase treatment did not affect the activation rate constant of α1H from
HEK cells incubated in normal glucose medium.

NG (n=25), NG + 30 minutes Neu (n=8), HG (n=26); observed differences were not statistically
significant (p>0.05 at all voltages; one-way ANOVA).
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τdeac (ms)
V (mV)

NG

NG + 30 Neu

HG

-60

5.01 ± 0.64

5.56 ± 1.03

4.81 ± 0.61

-70

4.99 ± 0.54

4.67 ± 1.04

4.30 ± 0.38

-80

4.51 ± 0.42

6.18 ± 1.39

4.03 ± 0.44

-90

4.48 ± 0.43

4.00 ± 0.54

4.11 ± 0.34

-100

3.85 ± 0.23

5.35 ± 1.07

3.95 ± 0.34

-110

3.42 ± 0.40

3.39 ± 0.54

3.17 ± 0.35

-120

2.95 ± 0.23

3.13 ± 0.52

3.47 ± 0.49

-130

3.19 ± 0.39

3.18 ± 0.46

3.86 ± 0.73

-140

3.38 ± 0.30

3.60 ± 0.25

3.76 ± 1.17

Table 12. Neuraminidase treatment does not affect the deactivation rate constant of α1H
from HEK cells incubated in normal glucose medium.

NG (n=25), NG + 30 minutes Neu (n=9), HG (n=26); observed differences were not statistically
significant (p>0.05 at all voltages; one-way ANOVA).
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NG
SSA V50 -29.02
(mV ) ± 0.86

NG
+ 30 Neu

p-value
NG vs.
NG + 30 Neu

HG

p-value
NG vs. HG

-28.70
± 1.84

0.860

-33.04
± 1.02

0.004

Table 13. Neuraminidase treatment did not affect steady-state activation V50 values from
cells incubated in normal glucose medium.

As was previously stated, culture in HGM is associated with a significant depolarizing shift in SSA
V50 values. Neu had no effect on SSA V50 values from cells incubated in NGM; NG (n=25), NG +
30 minutes Neu (n=9), HG (n=26) (unpaired Student’s t-test).

SSI V50
(mV )

NG

NG
+ 30 Neu

p-value
NG vs.
NG + 30 Neu

HG

p-value
NG vs. HG

-55.41
± 0.74

-56.30
± 1.02

0.524

-55.08
± 0.79

0.762

Table 14. Neuraminidase treatment did not affect steady-state inactivation V50 values from
cells incubated in normal glucose medium.

NG (n=25), NG + 30 minutes Neu (n=9), HG (n=26); observed differences were not statistically
significant (p-values given in table; unpaired Student’s t-test).
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Addition of negatively-charged neuraminic acid (NANA) moieties does not
affect CaV3.2 channel properties
It is conceivable that the effects seen in hyperglycemia are due to an
increase in negatively-charged sialic acids located on proteins or lipids that alter
the surface potential and charge distribution near the channel. As a control, I
added 1 µM NANA to the external solution during electrophysiological recordings.
Addition of NANA to cells incubated in either NGM or HGM had no effect on
current density (NG: -7.80 ± 0.78 pA/pF; n=12; NG+NANA: -7.57 ± 1.06 pA/pF;
n=8; HG: -16.35 ± 1.67 pA/pF; n=8; HG+NANA: -14.82 ± 2.26 pA/pF; n=8; Figure
17), kinetic properties (τon, τoff, τdeac; Tables 15-17), or steady-state properties
(SSA or SSI V50 values; Tables 18 and 19). The results of this experiment infer
that a global alteration of charges is not responsible for the effects of
hyperglycemia; in other words, negative charges must be specifically located:
either within the mouth of the channel pore on N-linked glycans or nearby in the
channel’s lipid environment.

Discussion
One objective of this aim was to confirm that hyperglycemia alters CaV3.2
channel properties in vitro. The significant increase in current density observed
in hyperglycemic conditions is in accord with previously reported data from both
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Figure 17: Addition of N-acetylneuraminic acid did not affect calcium current in HEK-α
α1H
cells.

(A) Protocol and representative calcium current traces evoked from a 240 ms depolarizing pulse
from VH= -100 mV to VT= -25 mV from cells incubated in NGM (5.6 mM) or HGM (25 mM). (B) IV relationships from cells cultured in NGM (open circles; n=12) or HGM (closed circles; n=8). (C)
I-V relationship from cells incubated in NGM (solid line), HGM (dashed line), NGM + 1 µM NANA
(orange circles; n=8), or HGM + 1 µM NANA (blue circles; n=8). NG and HG points and error
bars are removed for visual clarity. Data shown in B and C are means ± SEM. Observed
differences between control data and control + NANA data is not statistically significant at either
concentration of glucose (p>0.05, one-way ANOVA).
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τon (ms)
V
(mV)

NG

NG
+ NANA

HG

HG
+ NANA

-40

14.37
± 1.46

13.32
± 1.31

20.83
± 5.48

14.54
± 2.45

8.78
± 0.60
5.42
± 0.51
3.28
± 0.29
2.47
± 0.19
2.10
± 0.20
2.04
± 0.29
2.45
± 0.61

9.04
± 0.76
5.09
± 0.54
3.23
± 0.36
2.26
± 0.15
1.75
± 0.20
1.54
± 0.19
1.44
± 0.17

10.54
± 1.19
5.38
± 0.34
3.46
± 0.32
2.33
± 0.22
1.76
± 0.26
1.33
± 0.31
1.16
± 0.29

10.62
± 1.53
5.83
± 0.70
3.46
± 0.55
2.27
± 0.35
1.66
± 0.32
1.52
± 0.52
2.21
± 1.40

-30
-20
-10
0
10
20
30

Table 15. N-acetylneuraminic acid did not affect activation kinetics.

Activation time constants (τon) from cells cultured in NG (n=12), NG + NANA (n=8), HG (n=8), or
HG + NANA (n=8); data shown are mean ± SEM. Differences are statistically insignificant (oneway ANOVA; p>0.05 at all voltages).
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τoff (ms)
V
(mV)
-40
-30
-20
-10
0
10
20
30
40

NG
99.66
± 15.29
40.99
± 2.23
32.43
± 1.84
27.29
± 1.29
23.74
± 0.88
22.00
± 0.84
21.08
± 1.05
25.10
± 2.88
36.03
± 6.64

NG
+ NANA
109.00
± 25.06
41.06
± 2.46
30.77
± 1.77
26.26
± 1.41
23.66
± 0.98
22.64
± 1.07
22.44
± 1.49
22.62
± 2.82
34.02
± 9.91

HG
81.12
± 13.50
31.78
± 3.56*
26.98
± 3.13
22.99
± 2.27
20.00
± 1.55*
18.49
± 1.27*
17.59
± 1.12*
16.72
± 1.12*
19.58
± 3.20

HG
+ NANA
87.70
± 10.42
39.06
± 6.61
29.00
± 3.75
24.90
± 3.09
21.52
± 2.35
19.68
± 1.90
18.67
± 1.76
17.64
± 1.63
15.37
± 2.00*

Table 16. N-acetylneuraminic acid did not affect inactivation kinetics.

Inactivation time constants (τoff) from cells cultured in NG (n=12), NG + NANA (n=8), HG (n=8), or
HG + NANA (n=8); data shown are mean ± SEM. *p<0.05 compared to NG data, one-way
ANOVA. HG + NANA data is not statistically different from NG or HG data.
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τdeac (ms)
V
(mV)

NG

NG
+ NANA

HG

HG
+ NANA

-60

7.26
± 1.90

4.86
± 1.10

3.52
± 0.59

3.82
± 0.47

4.60
± 0.90
5.73
± 1.39
5.25
± 0.97
3.92
± 0.41
4.22
± 0.41
3.93
± 0.73
3.67
± 0.33
4.09
± 0.53

4.48
± 0.68
5.13
± 1.70
5.15
± 0.81
5.45
± 0.97
4.11
± 0.88
3.73
± 0.59
4.02
± 0.87
3.34
± 0.86

5.85
± 1.72
7.15
± 1.30
4.87
± 0.84
4.86
± 0.53
3.63
± 0.31
3.26
± 0.46
4.55
± 0.83
3.11
± 0.92

4.79
± 0.99
5.42
± 0.86
4.82
± 0.59
3.61
± 0.32
4.68
± 0.70
5.31
± 1.97
3.71
± 0.71
8.85
± 3.43

-70
-80
-90
-100
-110
-120
-130
-140

Table 17. N-acetylneuraminic acid did not affect deactivation kinetics.

Deactivation time constants (τdeac) from cells cultured in NG (n=12), NG + NANA (n=8), HG (n=8),
or HG + NANA (n=8); data shown are mean ± SEM. Differences are statistically insignificant at all
voltages (p>0.05; one-way ANOVA).
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SSA V50
(mV)

NG

NG + NANA

HG

HG + NANA

-24.73
± 1.37

-27.78
± 1.46

-29.14
± 1.50*

-29.07
± 1.95

Table 18. N-acetylneuraminic acid did not affect steady-state activation V50 values.

NG (n=12), HG (n=8), NG + NANA (n=8), HG + NANA (n=8). *p<0.05 compared to NG data
(one-way ANOVA). HG + NANA data is not statistically different compared to NG or HG data.

SSI V50
(mV)

NG

NG +
NANA

HG

HG +
NANA

-52.92
± 0.93

-54.98
± 1.33

-51.95
± 0.65

-51.97
± 1.00

Table 19. N-acetylneuraminic acid did not affect steady-state inactivation V50 values.

NG (n=12), HG (n=8) NG + NANA (n=8), HG + NANA (n=8); observed differences are statistically
insignificant (p>0.05; one-way ANOVA).
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in vitro and in vivo studies (Li et al. 2005; Jagodic et al. 2007; Latham et al. 2009;
Messinger et al. 2009; Shankarappa 2010; Shankarappa et al. 2011). HEK-α1H
cells cultured in hyperglycemic conditions exhibited a leftward, hyperpolarizing
shift in steady state activation, meaning that during a depolarization event,
channels are more likely to be in an open state. This change in open probability
is likely responsible for the increased current density seen in cells cultured in
hyperglycemic conditions. On the other hand, the observed shift in τoff values
would seem counter-intuitive, as faster channel inactivation could lead to
decreased total current entering the cell. However, this was a discrete change
that would only account for a 3% decrease of calcium influx, which is unlikely to
be of physiological significance in the regulation of CaV3.2 calcium current in
hyperglycemia.

More likely, the change in τoff observed in hyperglycemia is

unrelated to the other observed changes and is probably due to alterations in the
sialylation status of amino acids important for regulating inactivation kinetics of
the channel.
Since T-type channels (particularly CaV3.2) are crucial in pain pathways
(Todorovic et al. 2002; Kim et al. 2003; Bourinet et al. 2005; Nelson et al. 2006;
Choi et al. 2007) and have been implicated in the pathology of diabetic
neuropathy (Matthews et al. 2001; Dogrul et al. 2003; Flatters et al. 2004;
Bourinet et al. 2005; Pathirathna et al. 2005; Jagodic et al. 2007; Messinger et al.
2009; Zamponi et al. 2009), it is reasonable to suggest that hyperglycemia-
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associated alterations in CaV3.2, such as increased current density and channel
open probability contribute to this disease state.
In this chapter, I first showed that CaV3.2 T-type calcium current density is
significantly increased in cells cultured in hyperglycemic conditions. This is in
line with previous reports in DRG neurons from in vivo studies with diabetic
rodents (Hall et al. 1995; Jagodic et al. 2007; Latham et al. 2009; Messinger et
al. 2009; Shankarappa et al. 2011) and non-diabetic rat DRG neurons exposed
to diabetic serum (Ristic et al. 1998), as well as in vitro studies with neonatal
ventricular cardiomyocytes and HEK-α1H cells cultured in hyperglycemic
conditions (Li et al. 2005; Shankarappa 2010). Similar results were shown in
studies of pancreatic β cells exposed to diabetic human (Juntti-Berggren et al.
1993) or rat serum (Kato et al. 1994; Kato et al. 1996).
Next I showed that inactivation kinetics from cells cultured in
hyperglycemic conditions were significantly faster. Again, this was a discrete
change and is unlikely to be of physiological significance in the regulation of
CaV3.2 calcium current density in hyperglycemia.

I then showed that cells

cultured in hyperglycemic conditions had a significant increase in channel open
probability (SSA) without a significant net change in channel availability (SSI),
which is in contrast to some other reports. Some studies describe an increase in
channel availability in DRG neurons isolated from diabetic rats (Jagodic et al.
2007; Shankarappa et al. 2011); others report no hyperglycemia-associated
change in availability in DRG neurons (Ristic et al. 1998), ventricular myocytes,
or HEK cells (Li et al. 2005; Shankarappa 2010). No other studies on VGCCs

have shown a shift in open probability in hyperglycemia.
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These conflicting

results could be due to expression systems (i.e. cell type) or experimental
conditions.
After de-sialylation with neuraminidase, there was reversal of the changes
associated with hyperglycemia, without alteration of the properties of cells
cultured in normal glucose medium. First, there was a significant decrease in Ttype calcium current density from cells cultured in HGM after Neu treatment.
This result was also described in an abstract in which DRG neurons and CaV3.1or CaV3.2-expressing HEK cells were treated with neuraminidase (Todorovic et
al. 2009). These results are in direct contrast to a report stating that T-type
current was enhanced in guinea pig ventricular myocytes treated with
neuraminidase (Yee et al. 1989); however, in this study the authors report that
only 25-50% of the myocytes have significantly increased current. The rest of
the cells assayed show slightly decreased current. Additionally, batches of cells
isolated on different dates show differing results (i.e. no effect after some
isolations).

The group also used three different types of neuraminidase.

In

another study using cardiomyocytes isolated from rabbit sinoatrial node,
neuraminidase (type X) treatment was associated with increased T-type current
in five of nine cells tested and decreased current in the other four (Fermini et al.
1991). These variable results are likely due to the fact that the prevailing T-type
channel in ventricular myocytes and in the sinoatrial node is α1G and not α1H as in
our current study. In addition, this discrepancy may be due to the experimental
design (i.e. type of neuraminidase) and model systems used; channels show
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different glycosylation signatures depending on cell type, cell location or species
used (Stocker et al. 2006). Lipid and ganglioside composition also vary based on
these parameters and may affect channel function differently (Kotani et al. 1993).
With neuraminidase treatment, I observed a reversal of the accelerated
inactivation kinetics and depolarizing shift of channel open probability seen in
cells cultured in HGM. In accordance to our data, the study using the same HEK
model system as this thesis also reported slower inactivation kinetics after
treatment with neuraminidase.

Additionally, they described slower activation

kinetics with Neu treatment, which we did not observe in our study (Todorovic et
al. 2009). This slight discrepancy could be due to experimental conditions or
slight differences in the α1H clone used.
Another change that was associated with neuraminidase treatment of cells
cultured in HGM was a decrease (hyperpolarizing shift) in channel availability.
Todorovic et. al (2009) reported the exact opposite phenomenon (an increase in
availability). Changes in channel availability may be due to many factors such as
channel glycosylation or lipid composition. In the abstract, Todorovic et. al. do
not report on treatment duration, temperature, or type of neuraminidase used; the
differential changes in channel availability seen between their study and ours
may lie in experimental differences or α1H clone used.
The result showing that channel availability is increased in cells cultured in
high glucose (but not normal glucose) after treatment with neuraminidase
suggests that there is a concomitant change occurring in hyperglycemia that is
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uncovered only with removal of sialic acid. Perhaps there is complex regulation
that occurs as a result of the altered glycosylation status of the channel and
altered membrane composition, in which the alterations in channel glycosylation
and ganglioside composition cancel each other out, in terms of their effects on
channel availability.

The data suggest that the type of glycan added to the

protein during glycosylation is different than in normal physiological conditions,
and that this change is exposed when the membrane contains only simple
gangliosides, such as after neuraminidase treatment when complex gangliosides
are converted to GM1 (Wu et al. 1991).
By the law of mass action, reactions requiring glucose will be pushed
toward their products when there is increased sugar in the blood or culture
medium. Consequently, glucose can be converted into other sugars (sialic acid
for example) that can be added to lipids or proteins via glycosylation. Attachment
of negatively-charged sialic acid residues to CaV3.2 or elements in its
environment could alter channel properties directly by association with complex
gangliosides or by a change in conformation of the channel, or indirectly by
altering surface charges that could affect the way calcium is brought to the
channel pore (Zhang et al. 1991).
In summary, the results in this chapter suggest that there is an alteration
in lipid and/or protein glycosylation that occurs in hyperglycemia, since removal
of sialic acids from HEK-α1H cells reverses the effects of culture in hyperglycemic
conditions in terms of current density, open probability, and inactivation kinetics.
That channel availability is altered in cells cultured in high glucose (but not
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normal glucose) after treatment with neuraminidase suggests there is a
concomitant change occurring in hyperglycemia that is exposed only after desialylation, such as altered oligosaccharide type attached to the channel via Nglycosylation. A future study which would determine if this were the case would
be to first use site-directed mutagenesis to establish which of the asparagine
residues in the channel are glycosylated; we have identified four possibilities.
These arginines are located on the external side of the membrane at positions
192 (IS3-S4 linker), 271 (IS5-S6), 1466 (IIIS5-S6), and 1710 (IVS3-S4 linker),
which, as I reviewed in the introduction, have been postulated to be important for
inactivation (S3-S4 and S5-S6 linkers) (Hans et al. 1999) and the voltagedependence of activation (S5-S6 linkers) (Khosravani et al. 2004). Next, we
would use mass spectrometry to determine the composition of each
oligosaccharide chain in eu- and hyperglycemia.
Based on this study, we have determined that this in vitro cell culture
model responds similarly to in vivo models of diabetic hyperglycemia that have
previously been described.

De-sialylation with neuraminidase reverses the

alterations in current density, τoff, and channel open probability and exposes an
alteration in channel availability, suggesting that the glycosylation status of the
channel as well as its microenvironment are altered.

CHAPTER FOUR
DETERMINATION OF THE EFFECTS OF GM1 ON CAV3.2 CALCIUM
CURRENT AND ITS DEPLETION IN HYPERGLYCEMIA
Abstract
Diabetic neuropathy is a common complication of diabetes; this nervous
system damage is associated with enhanced α1H T-type calcium channel
function, resulting in heightened neuronal excitability and chronic pain (Hall et al.
1995; Jagodic et al. 2007; Latham et al. 2009; Messinger et al. 2009;
Shankarappa et al. 2011).
One biochemical change caused by hyperglycemia is altered membrane
lipid composition (Pratt et al. 1969; Gerbi et al. 1998; Yee et al. 2010), including
that of the sialic acid-containing gangliosides (Kumar et al. 1993; Kamboj et al.
2009), which are enriched in the nervous system and have numerous important
functions. The monosialoganglioside GM1 is greatly decreased in experimental
hyperglycemia (Cho et al. 2010), likely because excess glucose is used in
reactions that convert it into complex poly-sialic acid-containing gangliosides.
Here we hypothesize that GM1 is an inhibitory modulator of the α1H T-type
calcium channel, and that GM1 depletion during hyperglycemia leads to
disinhibition of the channel and thus, increased channel function. To test this
hypothesis, CaV3.2 function was assayed using whole-cell voltage clamp
88
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electrophysiology to measure current density and biophysical properties in HEK293 cells stably transfected with the α1H T-type calcium channel, cultured either
in eu- or hyperglycemic conditions.

The co-localization of α1H with GM1 was

probed using confocal microscopy, followed by functional assays. The effect of
GM1 on α1H channel function was tested by direct addition (1 µM), using a similar
ganglioside, GD1A, as a control. The specificity and reversibility of GM1 was also
probed using cholera toxin subunit B (CtxB, 5 µg/mL), GM1’s natural binding
partner.
Cells grown in normal glucose medium (with normal levels of endogenous
GM1) were treated with CtxB, resulting in enhancement of α1H current density,
accelerated inactivation kinetics, and increased open probability; these effects
mimicked the effect of culture in high glucose medium. Cells cultured in high
glucose medium were not affected by CtxB, in line with the reported absence of
GM1 in these conditions. This data suggests that endogenous GM1 acts as an
inhibitory modulator of the channel.
Next I supplied GM1 to cells grown in hyperglycemic conditions and tested
its effects on α1H, and its reversibility by further addition of CtxB. The addition of
GM1 reversed the increased current density and accelerated inactivation kinetics
induced by high glucose, but it did not change the open probability, suggesting
that there is a concomitant change occurring in hyperglycemia other than GM1
depletion, such as altered N-glycosylation status. Subsequent addition of CtxB
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reversed the changes in current density and inactivation kinetics induced by GM1.
These results corroborate our conclusion that the inhibitory effect of GM1 is
specific. Negative controls included the ganglioside GD1a or direct addition of free
sialic acid. We propose that α1H inhibition by GM1 occurs as a result of the
location of the sialic acid on the sub-terminal galactose moiety. The conversion
of GM1 to the more complex ganglioside GD1a likely causes steric or chargeinduced hindrance due to the presence of an additional sialic acid moiety. This
results in a loss of the ability to inhibit the channel.
In conclusion, we demonstrated that GM1 is an endogenous inhibitor of the
CaV3.2 T-type calcium channel. Our data suggest that GM1‘s depletion during
hyperglycemia leads to disinhibition of the channel, possibly contributing to the
enhanced excitability occurring in neuropathic pain.

Introduction
Diabetes Mellitus is a group of metabolic disorders in which blood glucose
levels are abnormally high. Diabetic levels of D-glucose cause increased CaV3.2
calcium channel current density both in vivo and in vitro (Li et al. 2005; Jagodic et
al. 2007; Latham et al. 2009; Messinger et al. 2009; Shankarappa 2010;
Shankarappa et al. 2011). Within the metabolic and cellular changes occurring
during diabetic hyperglycemia, there are several alterations to lipid composition,
including that of gangliosides. Discussed in more detail in chapter one,
gangliosides are complex sialic acid-containing glycosphingolipids (Sastry 1985)
with a combination of galactose, N-acetylgalactose, and sialic acid moieties on a
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ceramide backbone. Their biosynthesis is regulated by five sialyltransferases
and six glycosyltransferases (Yu et al. 2004).
Neuronal membranes are naturally enriched with gangliosides, especially
GM1, GD1a, GD1b, and GT1b in the human nervous system (Sastry 1985; Lopez et
al. 2009). Expression is developmentally regulated (Fishman et al. 1976) and is
regionally specific (Kotani et al. 1993) due to differential expression of
biosynthetic enzymes.
Gangliosides serve many functions in neuronal membranes; a few of their
postulated functions include regulation of cell morphology (Simmons et al. 1975),
binding and release of neurotransmitters and regulation of the cell cycle (Misasi
et al. 1997), as well as functioning as membrane receptors for many toxins (van
Heyningen 1959; Simpson et al. 1971; Simpson et al. 1971; Cuatrecasas 1973;
Holmgren et al. 1973; King et al. 1973; Merritt et al. 1994). Additionally, they are
known to regulate the function of signaling proteins such as growth factor
receptors (Lopez et al. 2009).
Since ganglioside expression is tightly regulated both by region and
developmental stage, altering the concentration of specific ganglioside species is
associated with various disease processes, including diabetes.

Kumar and

Menon reported a decrease in gangliosides in brain samples from diabetic rats;
insulin treatment of these rats restored normal glycolipid levels (Kumar et al.
1993). Several other groups have shown that membrane lipid composition is
altered in both diabetic patients and experimentally-induced diabetic rats. Other
studies show overall decreased levels of gangliosides in diabetic rat
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synaptosomal membranes (Kamboj et al. 2009), as well as altered fatty acid
composition and increased proportions of triglycerides and cholesterol in diabetic
rat brain (Pratt et al. 1969) and sciatic nerve (Gerbi et al. 1998). A study on rat
retina similarly showed altered poly-unsaturated fatty acid composition (Yee et al.
2010). In diabetic rat pancreas, GM3 proportion increases and GT3, GT2, and GQ1c
proportions decreased (Saito et al. 1999).

Additionally, as a part of the

autoimmune response of diabetes, the serum of diabetic patients contains
autoantibodies against gangliosides GM1, GM2, GM3, GD1a, GD1b, GD3, GT1b, GT3,
and GM2-1 (Lucchetta et al.; Gillard et al. 1989; Tiberti et al. 1995; Dotta et al.
1996 Sep; Dotta et al. 1997; Matà et al. 2004).
Interaction with gangliosides can affect the properties and function of
proteins in neuronal membranes. Several lines of evidence suggest a role for the
monosialoganglioside GM1 on calcium homeostasis.

Pre-treatment with GM1

prevents glutamate-, kainate-, and TOPA- (2,4,5-trihydroxyphenylalanine, an
AMPA receptor agonist) induced neurotoxicity in rat hippocampal and cerebellar
granular neurons (Favaron et al. 1988 Oct; Manev et al. 1990; Skaper et al.
1991; Skaper et al. 1992; Avrova et al. 1998) and in chicken retinal neurons
(Facci et al. 1990).

GM1 is postulated to prevent the protracted elevation in

intracellular calcium that occurs after exposure to high levels of NMDA, AMPA or
kainate receptor agonists, such as glutamate (de Erausquin et al. 1990; Costa et
al. 1993; Hoffman et al. 1995 Jun).

Bachis et. al. postulate that GM1’s

neuroprotective effect may be mediated via TrkB (a tyrosine receptor kinase
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whose endogenous ligand is brain-derived neurotrophic factor, BDNF) (Bachis et
al. 2002).
Other evidence for GM1 affecting calcium homeostasis includes a study
that shows a decrease in intracellular free calcium levels via decreased calcium
influx in primary cultures of chick brain after addition of GM1 (Guérold et al. 1992
May); the authors propose that a change in membrane fluidity or permeability to
calcium ions – perhaps through calcium channel modulation – could be the root
of the effect.

In other reports, addition of CtxB increases intracellular free

calcium concentrations by increasing calcium influx in sensory neurons (Milani et
al. 1992), fibroblasts (Spiegel et al. 1988; Buckley et al. 1995), and Tlymphocytes (Dixon et al. 1987; Gouy et al. 1994). This effect is proposed to be
due to non-L- non-N-type voltage-gated calcium channels, as their specific
blockers did not affect calcium influx.

In neuroblastoma cells, 200 nM GM1 is

proposed to inhibit L-type calcium channels, with complete inhibition occurring
upon treatment with 2 µM GM1 (Carlson et al. 1994). In contrast, when similar
concentrations of GM1 were added exogenously to synaptosomal membranes,
calcium influx increased, likely via L-type calcium channels (Tanaka et al. 1997).
Additionally, when used at higher concentrations such as 10 or 100 µM, GM1 was
reported to activate L-type calcium channels in PC12 cells (Hilbush et al. 1992).
In cultured cerebellar granule neurons, GM1 appears to serve as an inhibitor of Ltype channels during the first week in vitro and then as an activator afterwards
(Wu et al. 1996); the authors suggest that GM1 may modulate the channel directly
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by acting as an agonist or antagonist, or indirectly via a second messenger
process such as kinase modulation. Antibodies against GM1 was associated with
activation of an amiloride-sensitive calcium entry pathway in Neuro2a cells,
possibly T-type calcium channels, although this possibility was not specifically
tested (Ravichandra et al. 1999).

The variable effects of GM1 on calcium

homeostasis shown by these studies are likely due to the differing cell types,
metabolic states, and developmental stages of the model systems used;
ganglioside composition and glycosylation status change due to these
parameters. In another study using rat thymocytes, GM1 sequestration with CtxB
altered membrane potential by regulating flux through calcium-sensitive
potassium channels (Mulhern et al. 1989). In addition to these direct effects, GM1
is known to regulate excitatory opioid receptor-mediated hyperalgesia by second
messenger modulation of potassium and calcium channels (Crain et al. 1990).
The objective of this aim was to test the hypothesis that altered
membrane ganglioside composition – specifically, a decreased concentration of
GM1 – contributes to the increased CaV3.2 channel function seen in
hyperglycemia.

To investigate this, I assayed for T-type calcium currents in

HEK-α1H cells cultured in NG or HG medium by whole-cell voltage clamp and
tested whether modifying the levels of ganglioside GM1 altered CaV3.2 T-type
current density or biophysical properties. To corroborate whether GM1 directly
modulates the channel (for GM1 structure see Figure 18), I tested the effect of
cholera toxin subunit B (CtxB) on cells after incubation in GM1, or by itself as a
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Figure 18. Structure of monosialotetrahexosylganglioside GM1.

Gangliosides are embedded in the membrane by ceramide, a lipophilic molecule consisting of
sphingosine and a fatty acid chain. Through specific additions of one glucose, two galactose,
one N-Acetylgalactosamine, and one N-Acetylneuraminic acid moiety to ceramide, GM1 is formed.
The N-acetylneuraminic acid moiety gives GM1 a negative charge at neutral pH.
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control. CtxB interacts with GM1, acting as a specific inhibitor of the ganglioside
(Figure 19). I used NANA and another ganglioside, GD1A, as controls for the
specificity of the effects of GM1.
In this study, we determined that GM1 is an endogenous inhibitory
modulator of the CaV3.2 channel and that GM1 depletion in hyperglycemia is
associated with increased channel function. Prevention of the interaction of GM1
with CaV3.2 in euglycemia using CtxB releases GM1‘s inhibitory effects.

Materials and Methods
HEK-293 cells stably transfected with α1H calcium channels (HEK-α1H)
were used for this study.

This in vitro model is ideal to assess changes to

CaV3.2, as other cellular components may increase the complexity of the data
and/or confound its interpretation. Cells were cultured in normal glucose medium
or high glucose medium for at least 24 hours.
NG medium contains 5.6 mM glucose, a similar level found in euglycemic
rats and humans (Shankarappa et al. 2011). Similarly, HG medium contains 25
mM glucose, which is comparable to the 27 mM blood glucose in rats with
experimental diabetes (Shankarappa 2010).

For reference, the American

Diabetes Association reports that a fasting blood glucose level higher than 126
mg/dL (~7 mM) is considered diabetic in humans.

Thus the experimental

conditions used in this study accurately represent blood glucose levels for both
normal

euglycemic

and

diabetic

hyperglycemic

rats

and

humans.
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Figure 19. Crystal structure of Cholera toxin subunit B bound to its receptor, GM1.

Cholera toxin consists of one A subunit and a pentamer of B subunits. Each B subunit contains
two alpha helices and two three-stranded anti-parallel β sheets. Hydrogen bonds form between
amino acids in the B subunit and the NANA and terminal galatose moieties of GM1. In this
diagram, each B subunit is bound to one molecule of GM1. Modified from Merritt et. al. 1994.
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To assay electrophysiological properties, whole-cell voltage clamp was
used to measure current density, current-voltage relationships, and kinetic
properties including the time constants of current activation, inactivation, and
deactivation, as well as properties of steady-state activation and inactivation in
CaV3.2.
In this chapter, I explored the possibility that hyperglycemia-induced
changes in membrane GM1 composition directly alter CaV3.2 calcium currents.
During electrophysiological recordings, I added 1 µM GM1 or GD1A to cells
cultured in HG or NG medium.

I added 5 µg/mL CtxB to cells during

electrophysiology to investigate if its addition reversed the effects of GM1 on
CaV3.2 calcium currents. In experiments discussed in detail in chapter three, I
added 1 µM NANA during electrophysiological recordings to explore the
possibility that the altered current was solely due to electrostatic effects on the
channel.
Ganglioside GM1 (Carbosynth Ltd., Berkshire, UK) or GD1a (Sigma-Aldrich,
St. Louis, MO) solutions were prepared by dissolving lyophilized ganglioside in
methanol to a concentration of 10 mM.

Before addition to cells during

electrophysiological recordings, gangliosides were diluted 1:10,000 in external
solution (1 µL in 10 mL; for composition of external solution, see chapter two),
giving a final concentration of 1 µM GM1 or GD1a. For CtxB solutions (SigmaAldrich, St. Louis, MO), 500 µg of CtxB was dissolved in one mL of sterile deionized water, and then diluted 1:100 in external solution (100 µL in 10 mL) for

use in electrophysiological studies.
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For NANA solutions, lyophilized N-

acetylneuraminic acid was dissolved in sterile de-ionized water to a concentration
of 10 mM. This solution was then diluted 1:10,000 (1 µL in 10 mL; 1 µM) in
external solution before use.
To

determine

if

the

CaV3.2

calcium

channel

colocalizes

with

monosialoganglioside GM1, cells cultured in normal glucose medium were plated
on glass coverslips, fixed, and treated with FITC-conjugated CtxB and anti-α1H
polyclonal primary antibodies followed by secondary antibodies with a red
fluorophore.

Using confocal microscopy, Z-stack images were taken.

CtxB

images were merged with CaV3.2 images to determine overlap (colocalization).

Results
Disruption of the interaction between GM1 and CaV3.2 resulted in increased
current density to levels similar to those seen in hyperglycemia
To determine whether the monosialoganglioside GM1 is an endogenous
inhibitory modulator of the CaV3.2 calcium channel under normal physiological
conditions, preclusion of the interaction of GM1 and CaV3.2 was tested in HEK-α1H
cells cultured in NGM using CtxB, the specific binding partner of GM1. As stated
in the previous chapter, cells cultured in HGM (-13.56 ± 1.01 pA/pF; n=17) exhibit
significantly increased current density compared to cells cultured in NGM (-9.53 ±
0.94 pA/pF; n=17; p<0.001). Upon addition of CtxB, cells incubated in NGM
exhibited significantly increased current density (-13.54 ± 1.89 pA/pF; n=10)
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compared to cells cultured in NGM (p<0.05; Figures 20c, 21a). In contrast, cells
cultured in HGM did not show statistically different current densities before
(-13.56 ± 1.01 pA/pF; n=17) and after (-14.53 ± 2.16 pA/pF; n=9) addition of CtxB
(P = 0.646; Figure 20d, 21a). This data shows that in normal glucose conditions,
GM1 is a constituent of the plasma membrane in HEK cells, and that its
endogenous effect on α1H is inhibitory.

Disruption of the GM1-CaV3.2 interaction: effect on kinetic properties
Cells cultured in HGM exhibited significantly faster τoff values compared to
cells cultured in NGM. Interestingly, addition of CtxB to cells cultured in NGM
was associated with significantly faster τoff values compared to controls.
Treatment with CtxB resulted in τoff values that were statistically similar to cells
cultured in HGM (at -20 mV: NG: 30.57 ± 1.59 ms, n=16; NG+CtxB: 25.29 ± 1.36
ms, n=10; HG: 25.55 ± 1.52 ms, n=17; NG vs. NG+CtxB, p<0.05; Figure 22 and
Table 20).

This result shows that GM1 sequestration by addition of CtxB in

euglycemia successfully removed the effect that GM1 had on inactivation kinetics.
In contrast, CtxB addition to cells cultured in HGM was associated with τoff values
that were statistically similar to cells cultured in HGM without CtxB addition
(Figure 22c).
Addition of CtxB was not associated with changes in τon or τdeac values
(Tables 21, 22).
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Figure 20. Addition of cholera toxin subunit B increased T-type current density in HEK-α
α1H
cells cultured in normal glucose medium.

(A) Protocol and representative calcium current traces evoked from a 240 ms depolarizing pulse
from VH= -100 mV to VT= -25 mV from cells incubated in NGM (5.6 mM) or HGM (25 mM). (B) IV relationships from cells cultured in NGM (open circles; n=17) or HGM (closed circles; n=17).
(C) I-V relationship from cells incubated in NGM (solid line; n=17), HGM (red dashed line; n=17),
and NGM + 5 µg/mL CtxB (green circles; n=10). (D) I-V relationship from cells incubated in NGM
(solid line; n=17), HGM (red dashed line; n=17), and HGM + 5 µg/mL CtxB (red circles; n=9). In C
and D, NG and HG points and error bars are removed for visual clarity. Data shown in B-D are
means ± SEM.
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Figure 21. Treatment with cholera toxin subunit B increased peak calcium current density
in HEK-α
α1H cells cultured in normal glucose medium.

(A) Bar graph comparing peak current densities from figure 20B-D. (B) I-V relationship of each
condition normalized to its own peak. A shift in the peak of the I-V curve indicates a possible
alteration of steady-state properties.
Student's t-test compared to NG data.

Data shown in A is mean ± SEM. *p<0.05, unpaired
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Figure 22. Effect of cholera toxin subunit B on inactivation rate constants.

(A) Protocol and representative T-type calcium current trace evoked by a 400 ms depolarizing
pulse from VH= -90 to VT= -20 mV from HEK-α1H cells. Inactivation rate constants (τoff) are
measured in ms; *p≤0.05, comparing NG + CtxB (B) or HG + CtxB (C) to NG data (unpaired
Student’s t-test).
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τoff (ms)
V
(mV)
-40
-30
-20
-10
0
10
20
30
40

NG
96.16
± 14.71
39.13
± 2.14
30.57
± 1.59
25.63
± 1.12
22.37
± 0.84
20.72
± 0.70
19.68
± 0.64
22.09
± 1.36
29.85
± 3.34

NG
+CtxB
86.54
± 13.66
33.65
± 1.95
25.29
± 1.36*
21.86
± 1.16*
19.69
± 1.00*
18.27
± 0.82*
17.42
± 0.95*
20.62
± 2.91
24.74
± 4.10

HG
66.79
± 6.52*
34.39
± 2.56
25.55
± 1.52*
21.39
± 1.07*
19.35
± 0.94*
17.88
± 0.80*
17.25
± 0.77*
19.59
± 1.76
30.63
± 5.41

HG
+CtxB
104.82
± 22.92
40.50
± 3.72
25.32
± 1.51*
21.01
± 1.17*
19.10
± 1.18*
17.89
± 1.10*
17.19
± 1.11*
19.81
± 2.71
23.20
±4.21

Table 20. Effect of cholera toxin subunit B on inactivation rate constants.

NG (n=16), NG + CtxB (n=10), HG (n=17), HG + CtxB (n=9); *p<0.05 compared to NG data; oneway ANOVA.
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V
(mV)
-40
-30
-20
-10
0
10
20
30

NG
15.19
± 1.75
10.90
± 1.25
6.04
± 0.56
3.64
± 0.30
2.65
± 0.20
2.10
± 0.17
1.84
± 0.23
1.93
± 0.47

τon (ms)
NG
+ CtxB
14.05
± 2.23
10.04
± 1.41
5.89
± 0.40
3.49
± 0.29
2.28
± 0.18
1.70
± 0.16
1.24
± 0.13
2.03
± 0.93

HG
14.57
± 1.68
8.26
± 0.58
5.44
± 0.41
3.36
± 0.27
2.24
± 0.19
1.66
± 0.16
1.34
± 0.19
1.34
± 0.30

HG
+ CtxB
13.14
± 2.91
9.48
± 0.72
6.63
± 0.69
3.83
± 0.31
2.43
± 0.18
1.76
± 0.16
1.47
± 0.17
1.36
± 0.20

Table 21. Effect of cholera toxin subunit B on activation rate constants.

NG (n=17), NG + CtxB (n=10), HG (n=17), HG + CtxB (n=9); observed differences were not
statistically significant (p>0.05 at all voltages; one-way ANOVA).
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V
(mV)
-60
-70
-80
-90
-100
-110
-120
-130
-140

NG
6.78
± 1.37
4.61
± 0.62
4.45
± 0.40
5.91
± 0.74
4.54
± 0.62
4.26
± 0.34
3.37
± 0.26
3.99
± 0.60
3.62
± 0.44

τdeac (ms)
NG
+ CtxB
4.07
± 0.43
4.83
± 0.82
3.93
± 0.44
4.88
± 0.70
5.06
± 1.40
4.10
± 0.72
5.24
± 1.36
3.82
± 1.11
5.91
± 1.80

HG
4.42
± 0.44
4.89
± 0.53
5.26
± 0.76
4.64
± 0.33
4.26
± 0.43
3.52
± 0.48
3.37
± 0.32
3.43
± 0.44
3.29
± 0.52

HG
+ CtxB
5.31
± 0.88
7.41
± 1.80
6.18
± 1.98
3.92
± 0.46
3.84
± 0.56
2.71
± 0.30
2.38
± 0.19
2.54
± 0.28
3.63
± 0.66

Table 22. Effect of cholera toxin subunit B on deactivation rate constants.

NG (n=17), NG + CtxB (n=10), HG (n=17), HG + CtxB (n=9); observed differences were not
statistically significant (p>0.05 at all voltages; one-way ANOVA).
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Disruption of the interaction between GM1 and CaV3.2: effect on steady-state
properties
As previously stated, cells cultured in HGM exhibit a significant
hyperpolarizing shift in channel open probability compared to cells cultured in
NGM, from -24.73 ± 1.23 mV (NG, n=17) to -29.43 ± 1.09 mV (HG, n=17).
Addition of CtxB to cells cultured in NGM was associated with a similar,
significant hyperpolarizing shift in open probability compared to control cells (NG
vs. NG+CtxB; -24.73 ± 1.23 mV; -29.32 ± 1.51 mV; n=17, 10; p=0.029). This
change is akin to the shift seen in hyperglycemia (Figure 23, Table 23). This
result suggests that the increased open probability seen in hyperglycemia is due
to decreased interaction of GM1 with the channel. In contrast, addition of CtxB to
cells cultured in HGM exhibited SSA V50 values statistically similar to cells
cultured in HGM without CtxB addition (HG+CtxB vs. HG: -27.42 ± 1.49 mV, 29.43 ± 1.09 mV; n=9, 17; p=0.288; Figure 24, Table 23), again suggesting that
decreased GM1–α1H interaction occurs during hyperglycemia. Addition of CtxB
was not associated with any changes in steady-state inactivation (Table 24,
Figure 25).

Replenishment of GM1 to cells grown in hyperglycemic conditions returned
current density to levels similar to euglycemia
Next, I determined whether replenishment of GM1 to HEK-α1H cells
cultured in HGM induced CaV3.2 current inhibition to a level similar to that

108

Figure 23. Treatment with cholera toxin subunit B mimicked the hyperpolarizing shift in
CaV3.2 channel open probability associated with hyperglycemic culture conditions.

(A) Protocol and representative calcium tail current evoked by a 12 ms depolarizing pulse from
VH= -90 mV to VP= -90 to 0 mV, followed by hyperpolarization to VT= -100 mV in HEK-α1H cells.
(B) Steady state activation curves obtained from cells cultured in NGM (open circles; n=17), HGM
(closed circles; n=17) or NGM + 5 µg/mL CtxB (green circles; n=10). Dashed lines indicate V50
values. (C) Bar graph comparing steady-state activation V50 values from B. Data shown are
mean ± SEM. *p<0.03 compared to NG data (unpaired Student's t-test).
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Figure 24. Treatment with cholera toxin subunit B did not affect CaV3.2 open probability in
HEK-α
α1H cells incubated in high glucose medium.

(A) Protocol and representative calcium tail current evoked by a 12 ms depolarizing pulse from
VH= -90 mV to VP= -90 to 0 mV, followed by hyperpolarization to VT= -100 mV in HEK-α1H cells.
(B) Steady state activation curves obtained from cells cultured in NGM (open circles; n=14), HGM
(closed circles; n=17) or HGM + 5 µg/mL CtxB (red circles; n=9). Dashed lines indicate V50
values. (C) Bar graph comparing steady-state activation V50 values from B. Data shown in B and
C are mean ± SEM. *p<0.01 compared to NG (unpaired Student's t-test). HG + CtxB data is not
significant from NG or HG data.
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Figure 25. Treatment with cholera toxin subunit B did not affect CaV3.2 availability.

(A) Protocol and representative calcium current traces evoked by a 1.5 s depolarizing pulse from
VH= -90 mV to VP= -110 to 0 mV, return to VH for 20 ms, followed by depolarization to VT= -30 mV
for 150 ms. (B) Steady state inactivation (SSI) curves obtained from cells cultured in NGM (open
circles; n=17), NGM + 5 µg/mL CtxB (green; n=10), HGM (closed circles; n=17), or HGM + 5
µg/mL CtxB (red; n=9). (C) Bar graph comparing V50 values from the curves in B. Data shown in
B and C are mean ± SEM. Observed differences are not statistically significant (p>0.05; one-way
ANOVA).
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NG
SSA V50
(mV)

-24.73
± 1.23

NG +
CtxB
-29.32
± 1.51*

HG

HG + CtxB

-29.43
± 1.09*

-27.42
± 1.49

Table 23. Effect of cholera toxin subunit B on steady-state activation V50 values.

NG (n=17), NG + CtxB (n=10), HG (n=17), HG + CtxB (n=9); *p<0.03 compared to NG data (oneway ANOVA). HG + CtxB data is not significant from NG or HG.

SSI V50
(mV)

NG

NG + CtxB

HG

HG + CtxB

-51.59
± 0.97

-53.73
± 1.40

-53.18
± 1.04

-51.89
± 1.76

Table 24. Addition of cholera toxin subunit B had no effect on steady-state inactivation.

NG (n=17), NG + CtxB (n=10), HG (n=17), HG + CtxB (n=9); p>0.05 in all cases (one-way
ANOVA).
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observed in cells cultured in NGM. As stated in the previous chapter, HEK-α1H
cells cultured in HGM exhibited significantly increased current density compared
to cells cultured in NGM (HG vs. NG: -13.56 ± 1.01 pA/pF vs. -9.53 ± 0.94 pA/pF;
n=17, 17; p<0.006). Upon addition of GM1, cells incubated in HGM exhibited
significantly decreased current density (-10.27 ± 0.99 pA/pF; n=16) compared to
control HGM cells (p=0.027; Figure 26c, 27a). In contrast, cells cultured in NGM
elicited statistically similar current density before (-9.53 ± 0.94 pA/pF; n=17) and
after (-9.27 ± 0.96 pA/pF; n=12) addition of GM1 (p=0.852; Figure 26d).
Endogenous GM1 in HEK cells cultured in normal glucose conditions effectively
inhibits α1H channels.

Increasing its concentration has no effect on current,

suggesting that the natural concentration of GM1 is high enough to modulate all
channels present.

On the other hand, culture in hyperglycemic conditions

diminishes GM1 levels, leading to a reduced inhibitory effect. Replenishment of
GM1 heightens the inhibitory effect to a similar level of cells cultured in euglycemic
conditions.
To assay the reversibility of the process, I added CtxB to cells grown in
HGM that had previously been treated with GM1.

As detailed above, cells

cultured in HGM (-13.56 ± 1.01 pA/pF; n=17) exhibited decreased current density
when treated with GM1 (-10.27 ± 0.99 pA/pF; n=16), in line with an inhibitory
effect of GM1 on CaV3.2. Subsequent treatment with CtxB returned the current
density to levels similar to the HG control (-15.41 ± 1.35 pA/pF; n=9; vs. HG:
p=0.288; vs. HG+GM1: p=0.005), effectively demonstrating the direct interaction
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Figure 26. Monosialoganglioside GM1 reversed D-glucose-associated increases in CaV3.2
current density.

(A) Protocol and representative calcium current traces evoked from a 240 ms depolarizing pulse
from VH= -100 mV to VT= -25 mV from cells incubated in NGM (5.6 mM) or HGM (25 mM). (B) IV relationships from cells cultured in NGM (open circles; n=17) or HGM (closed circles; n=17).
(C) I-V relationship from cells incubated in NGM (solid line; n=17), HGM (dashed red line; n=17),
and HGM + 1 µM GM1 (red circles; n=16). (D) I-V relationship from cells incubated in NGM (solid
line; n=17), HGM (dashed red line; n=17), and NGM + 1 µM GM1 (green circles; n=12). NG and
HG points and error bars are removed for visual clarity in C and D. Data shown in B-D are
means ± SEM.
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Figure 27. Treatment with monosialoganglioside GM1 reversed the T-type calcium current
increase associated with hyperglycemia.

(A) Bar graph comparing peak current densities from figure 26B-D. (B) I-V relationship of each
condition normalized to its own peak. A shifted peak current indicates a possible alteration in
steady-state properties; shifts can be seen more easily when I-V relationships are normalized.
Data shown in A is mean ± SEM. *p<0.05 compared to control HG data, unpaired Student's t-test.
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between CaV3.2 and GM1, and showing that the effect is reversible upon release
of this interaction.
Cells cultured in NGM have normal levels of endogenous GM1 in the
membrane, so addition of GM1 had no effect on current (-9.27 ± 0.96 pA/pF;
n=12). Further addition of CtxB again resulted in current disinhibition (-11.63 ±
1.15 pA/pF, n=12; compared to control cells: -9.53 ± 0.94 pA/pF, n=17), although
this increase did not reach statistical significance when compared to control NGM
cells (p=0.129). However, this further addition of CtxB was associated with a
significant increase in current density compared to cells cultured in NGM that
were treated with GM1 (p=0.047, unpaired Student’s t-test; Figure 28, 29).
The effect of hyperglycemia could be due to excess negative charges
present globally. Addition of NANA to HEK-α1H cells cultured in either HGM or
NGM produced no effect on current density (Figure 17).

This experiment is

described in greater detail in chapter three.

Effect of GM1 replenishment to cells grown in HGM on the kinetic properties
of T-type current
In line with the previous results, τon and τdeac values were indistinguishable
between experimental groups (Tables 25, 26). As stated above, cells cultured in
HGM exhibit a faster rate of inactivation compared to cells cultured in NGM.
Addition of GM1 to cells cultured in HGM reversed the τoff values such that they
were no longer significantly faster than cells cultured in NGM (for example, at -20
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Figure 28. Effect of GM1 and cholera toxin subunit B on CaV3.2 current density.

(A) Protocol and representative calcium current traces evoked from a 240 ms depolarizing pulse
from VH= -100 mV to VT= -25 mV from cells incubated in NGM (5.6 mM) or HGM (25 mM). (B) IV relationships from cells cultured in NGM (open circles; n=17) or HGM (closed circles; n=17).
(C) I-V relationship from cells incubated in NGM (black line; n=17), HGM (dashed red line; n=17),
HGM + 1 µM GM1 (cyan circles; n=16), and HGM + GM1 and 5 µg/mL CtxB (blue circles; n=9). (D)
I-V relationship from cells incubated in NGM (black line; n=17), HGM (dashed red line; n=17),
NGM + 1 µM GM1 (green circles; n=12), and NGM + GM1 and 5 µg/mL CtxB (yellow circles; n=12).
In C and D, NG and HG points and error bars are removed for visual clarity. Data shown in B-D
are means ± SEM.
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Figure 29: Effect of GM1 and cholera toxin subunit B on CaV3.2 calcium current density.

Bar graph comparing peak current densities from figure 28B-D. Data shown is mean ± SEM.
*p<0.03 compared to control HG data; # p<0.05 compared to respective +GM1 data; unpaired
Student's t-test.
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τon (ms)
NG
+GM1
+CtxB

HG

HG
+GM1

HG
+GM1
+CtxB

11.68
± 1.25

14.57
± 1.68

11.15
± 1.56

11.77
± 1.71

9.78
± 0.73

8.99
± 1.30

8.26
± 0.58

7.82
± 0.67

8.07
± 0.95

6.04
± 0.56

5.56
± 0.37

5.08
± 0.63

5.44
± 0.41

5.17
± 0.53

4.43
± 0.40

-10

3.64
± 0.30

3.30
± 0.25

3.01
± 0.34

3.36
± 0.27

0

2.65
± 0.20

2.28
± 0.16

2.11
± 0.23

2.24
± 0.19

2.02
± 0.15

1.89
± 0.20

10

2.10
± 0.17

1.73
± 0.19

1.53
± 0.15

1.66
± 0.16

1.28
± 0.10

1.28
± 0.17

20

1.84
± 0.23

1.27
± 0.16

1.37
± 0.12

1.34
± 0.19

0.99
± 0.07

0.92
± 0.17

30

1.93
± 0.47

1.04
± 0.13

1.28
± 0.14

1.34
± 0.30

0.98
± 0.16

0.74
± 0.18

V
(mV)

NG

NG
+GM1

-40

15.19
± 1.75

12.40
± 1.22

-30

10.90
± 1.25

-20

3.11
± 0.20

2.61
± 0.25

Table 25. Effect of GM1 and cholera toxin subunit B on activation rate constants from HEKα1H cells.

NG (n=17), NG + GM1 (n=12), NG + GM1 + CtxB (n=12), HG (n=17), HG + GM1 (n=13), HG + GM1
+ CtxB (n=9); observed differences were not statistically significant (p>0.05 at all voltages; oneway ANOVA).
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τdeac (ms)
NG
+GM1
HG
+CtxB

HG
+GM1

HG
+GM1
+CtxB

4.42
± 0.44

6.00
± 0.98

5.07
± 0.99

4.26
± 0.71

4.89
± 0.53

4.92
± 0.57

3.36
± 0.44

5.77
± 0.87

4.40
± 0.70

5.26
± 0.76

4.35
± 0.68

2.58
± 0.24

5.91
± 0.74

3.83
± 0.42

3.86
± 0.42

4.64
± 0.33

4.61
± 1.13

3.02
± 0.49

-100

4.54
± 0.62

4.71
± 1.04

4.18
± 0.80

4.26
± 0.43

4.71
± 1.08

4.83
± 1.28

-110

4.26
± 0.34

4.57
± 1.21

2.81
± 0.25

3.52
± 0.48

4.20
± 0.74

3.33
± 0.61

-120

3.37
± 0.26

3.23
± 0.66

2.95
± 0.31

3.37
± 0.32

2.74
± 0.50

4.73
± 1.05

-130

3.99
± 0.60

3.20
± 0.50

2.77
± 0.42

3.43
± 0.44

2.75
± 0.42

3.08
± 0.89

-140

3.62
± 0.44

2.46
± 0.28

4.67
± 1.00

3.29
± 0.52

4.95
± 2.64

1.76
± 0.39

V
(mV)

NG

NG
+GM1

-60

6.78
± 1.37

5.69
± 1.13

4.60
± 0.79

-70

4.61
± 0.62

6.62
± 1.83

-80

4.45
± 0.40

-90

Table 26. Effect of GM1 and cholera toxin subunit B on deactivation rate constants from
HEK-α
α1H cells.

NG (n=17), NG + GM1 (n=12), NG + GM1 + CtxB (n=12), HG (n=17), HG + GM1 (n=16), HG + GM1
+ CtxB (n=9); observed differences were not statistically significant (p>0.05 at all voltages; oneway ANOVA).
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mV: NG: 30.57 ± 1.59 ms, n=16; HG: 25.55 ± 1.52 ms, n=17; HG+GM1: 26.97 ±
1.64 ms, n=13; NG vs. HG, p=0.029; NG vs. HG+GM1, p=0.130; HG vs. HG+GM1,
p=0.534), suggesting that the depletion of GM1 in hyperglycemia affects the
kinetics of inactivation, and that its replenishment returns the kinetics to normal.
CtxB reversed the effect of GM1 in cells cultured in HGM (at -20 mV:
HG+GM1+CtxB: 21.27 ± 1.50 ms, n=9; NG vs. HG+GM1+CtxB, p<0.001), again
showing the specificity of GM1 for the α1H calcium channel. In cells incubated in
NGM, treatment with GM1 had no effect on τoff. Subsequent addition of CtxB was
associated with significantly faster τoff values (at -10 mV: NG: 25.63 ± 1.12 ms,
n=16; NG+GM1: 27.20 ± 1.65 ms, n=12; NG+GM1+CtxB: 21.84 ± 1.25 ms, n=13;
NG vs. NG+GM1+CtxB, p=0.032; Figure 30). The inactivation kinetics data is
summarized in Table 27. Again, as was reported in chapter three, effects on
CaV3.2 kinetic properties were not due to globally altered charges (Tables 1517).

Effect of GM1 replenishment on steady-state properties
As previously stated, cells cultured in HGM have a significant
hyperpolarizing shift in channel open probability that is reproducible in cells
cultured in NGM supplemented with CtxB to remove the effect of endogenous
GM1.

Addition of GM1 to cells cultured in NGM was not associated with an

alteration of SSA V50 values compared to cells without GM1 (NG: -24.73 ± 1.23
mV, n=17, compared to NG+GM1: -25.47 ± 1.33 mV, n=12; p=0.691); however,
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Figure 30. Effect of GM1 and cholera toxin subunit B on T-type inactivation kinetics.

(A) Protocol and representative CaV3.2 calcium current trace evoked by a 400 ms depolarizing
pulse from VH= -90 to VT= -20 mV from HEK-α1H cells. Inactivation rate constants (τoff) are
measured in ms. (B) *p≤0.05, comparing HG or HG+GM1+CtxB to NG data; # p<0.05 comparing
HG+GM1+CtxB to NG data. (C) *p<0.05 comparing NG+GM1+CtxB to NG data (unpaired Student’s
t-test).
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τoff (ms)
NG
+GM1
+CtxB

HG

HG
+GM1

HG
+GM1
+CtxB

49.78
± 4.63

66.79
± 6.52*

65.69
± 6.71

47.84
± 6.05

42.77
± 2.71

33.72
± 3.54

34.39
± 2.56

35.64
± 2.36

28.69
± 2.68*

30.57
± 1.59

33.24
± 2.09

26.11
± 1.91

25.55
± 1.52*

26.97
± 1.64

21.27
± 1.50*

-10

25.63
± 1.12

27.20
± 1.65

21.84
± 1.25*

21.39
± 1.07*

22.64
± 1.31

18.65
± 1.35*

0

22.37
± 0.84

23.38
± 0.97

19.63
± 1.02*

19.35
± 0.94*

20.28
± 1.15

17.19
± 1.20*

10

20.72
± 0.70

21.42
± 0.70

18.35
± 0.75*

17.88
± 0.80*

18.94
± 1.18

16.70
± 1.35*

20

19.68
± 0.64

20.61
± 0.92

17.46
± 0.68*

17.25
± 0.77*

18.88
± 1.30

15.85
± 1.14*

30

22.09
± 1.36

20.51
± 2.31

17.33
± 0.92*

19.59
± 1.76

18.21
± 1.39

17.62
± 2.25

40

29.85
± 3.34

25.10
± 4.46

20.80
± 1.54

30.63
± 5.41

29.27
± 7.37

18.60
± 2.45

V
(mV)

NG

NG
+GM1

-40

96.16
± 14.71

86.40
± 8.09

-30

39.13
± 2.14

-20

Table 27. Effect of GM1 and cholera toxin subunit B on inactivation rate constants.

NG (n=16), NG + GM1 (n=12), NG + GM1 + CtxB (n=13), HG (n=17), HG + GM1 (n=13), HG + GM1
+ CtxB (n=9); *p<0.05 compared to NG data; one-way ANOVA.
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subsequent addition of CtxB was associated with a significant hyperpolarizing
shift in channel open probability compared to cells cultured in NGM (-29.23 ±
1.80 mV, n=13; NG vs. NG+GM1+CtxB: p=0.042), akin to the shift seen in cells
cultured in hyperglycemic conditions (HG: -29.43 ± 1.09, n=17; Figure 31).
In contrast, addition of GM1 to cells cultured in HGM (-29.90 ± 1.37 mV;
n=13) was not associated with a reversal in SSA V50 values to the level of cells
cultured in NGM, but rather was statistically similar to cells cultured in HGM
(-29.43 ± 1.09 mV, n=17; HG vs. HG+GM1: p=0.788), a result we did not
anticipate. Addition of CtxB to these cells resulted in no significant alteration of
SSA V50 values (-33.29 ± 1.86 mV, n=9; HG vs. HG+GM1+CtxB: p=0.067; Figure
32, Table 28). This result indicates that there is a change in the glycosylation
status of the channel, or that there is an unaddressed, concomitant change that
occurs in hyperglycemia that affects steady state activation properties.
Cells incubated in NGM and HGM have indistinguishable steady-state
inactivation V50 values; however, when cells cultured in HGM (V50= -53.18 ± 1.04
mV, n=17) were treated with GM1 (-55.37 ± 1.28 mV, n=12), they exhibited a
significant leftward (hyperpolarizing) shift that was not reversible with subsequent
CtxB addition (-55.41 ± 1.71 mV, n=9; NG vs HG+GM1 or HG+GM1+CtxB:
p<0.05). This discrete shift indicates that cells cultured in HGM have decreased
CaV3.2 availability upon addition of GM1, which is not altered in the presence of
CtxB (Figure 33, Table 29).

These data indicate that there must be a

concomitant change occurring in hyperglycemia that only becomes evident after
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Figure 31. Effects of GM1 and cholera toxin subunit B on CaV3.2 open probability in HEKα1H cells incubated in normal glucose medium.

(A) Protocol and representative calcium tail current evoked by a 12 ms depolarizing pulse from
VH= -90 mV to VP= -90 to 0 mV, followed by hyperpolarization to VT= -100 mV in HEK-α1H cells.
(B) SSA curves obtained from cells cultured in NGM (open circles; n=17), HGM (closed circles;
n=17), NGM + 1 µM GM1 (green; n=12), or NGM + GM1 and 5 µg/mL CtxB (yellow; n=13). Dashed
lines indicate V50 values. (C) Bar graph comparing SSA V50 values from B. Data shown in B and
C are mean ± SEM. *p<0.05 compared to NG data (unpaired Student's t-test).
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Figure 32. GM1 did not reverse D-glucose-associated shift in CaV3.2 channel open
probability.

(A) Protocol and representative calcium tail current evoked by a 12 ms depolarizing pulse from
VH= -90 mV to VP= -90 to 0 mV, followed by hyperpolarization to VT= -100 mV in HEK-α1H cells.
(B) Steady state activation curves obtained from cells cultured in NGM (open circles; n=17), HGM
(closed circles; n=17), HGM + 1 µM GM1 (cyan circles; n=13), or HGM + 1 µM GM1 and 5 µg/mL
CtxB (blue circles; n=9). Dashed lines indicate V50 values. (C) Bar graph comparing steady-state
activation V50 values from B. Data shown are mean ± SEM. *p<0.01 compared to NG data
(unpaired Student's t-test).
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Figure 33. GM1 decreased CaV3.2 channel availability in HEK-α
α1H cells incubated in high
glucose medium.

(A) Protocol and representative calcium current traces evoked from a 1.5 s depolarizing pulse from
VH= -90 mV to VP= -110 mV to 0 mV, a 20 ms return to VH, and a 150 ms depolarizing pulse to VT=
-30 mV. Example shown represents traces with VP= -110, -70, -50, and 0 mV. (B) Steady state
inactivation (SSI) curves obtained from cells cultured in NGM (open circles; n=17), HGM (closed
circles; n=17), HGM + 1 µM GM1 (cyan circles; n=12) or HGM + 1 µM GM1 and 5 µg/mL CtxB (blue
circles; n=9). (C) Bar graph comparing data from B. Data in B and C are means ± SEM. *p<0.05
compared to NG data (unpaired Student's t-test).
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SSA V50
(mV)

NG

NG
+ GM1

NG
+ GM1
+ CtxB

-24.73
± 1.23

-25.47
± 1.33

-29.23
± 1.80*

HG

HG
+GM1

HG
+GM1
+ CtxB

-29.43
± 1.09*

-29.90
± 1.37*

-33.29
± 1.86*

Table 28. Effect of GM1 and cholera toxin subunit B on steady-state activation V50 values.

NG (n=17), NG + GM1 (n=12), NG + GM1 + CtxB (n=13), HG (n=17), HG + GM1 (n=13), HG + GM1
+ CtxB (n=9); *p<0.05 compared to NG data (one-way ANOVA).

SSI V50
(mV)

NG

NG
+ GM1

NG
+ GM1
+ CtxB

-51.59
± 0.97

-52.15
± 0.98

-53.83
± 1.27

HG

HG
+GM1

HG
+GM1
+ CtxB

-53.18
± 1.04

-55.37
± 1.28*

-55.41
± 1.71*

Table 29. Effect of GM1 and cholera toxin subunit B on steady-state inactivation V50 values.

NG (n=17), NG + GM1 (n=12), NG + GM1 + CtxB (n=12), HG (n=17), HG + GM1 (n=16), HG + GM1
+ CtxB (n=9); *p<0.05 compared to NG data (one-way ANOVA).
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addition of GM1, such as increased channel glycosylation. No shift in SSI was
observed in cells incubated in NGM upon addition of GM1 and/or CtxB.
Again, effects of GM1 and CtxB on steady-state properties were specific,
not due to a global alteration in negative charges, as was shown in chapter three
by addition of NANA (Tables 18, 19).

GM1 is a specific modulator of CaV3.2; GD1A replenishment had no effect on
CaV3.2 properties
The effects that GM1 has on T-type currents are specific, since addition of
a different ganglioside that is abundant in euglycemia, GD1a, does not have the
same inhibitory effect on cells cultured in HGM. GD1a has the same backbone
structure as GM1, with the only difference between the two being an additional
NANA on the terminal galactose moiety. Addition of GD1a to cells cultured in
HGM produced no effect on current density (Figure 34), kinetic properties (τon,
τoff, τdeac; Tables 30-32), or steady-state properties (SSA, SSI V50 values; Figures
35, 36 and Tables 33, 34). As is seen in Figure 35 and Table 33, the average
steady-state activation V50 value from cells cultured in HGM that were treated
with GD1a is not statistically different from that of cells cultured in NGM; however,
this value is also not statistically different from cells cultured in HGM.
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Figure 34. Addition of GD1A did not alter calcium current density in HEK-α
α1H cells incubated
in hyperglycemic conditions.

(A) Protocol and representative calcium current traces evoked from a 240 ms depolarizing pulse
from VH= -100 mV to VT= -25 mV from cells incubated in NGM (5.6 mM) or HGM (25 mM). (B) IV relationships from cells cultured in NGM (open circles; n=9) or HGM (closed circles; n=10). (C)
I-V relationship from cells incubated in NGM (solid line), HGM (dashed line), or HGM + 1 µM GD1A
(orange circles; n=9). NG and HG points and error bars are removed for visual clarity. Data
shown in B and C are means ± SEM.
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τon (ms)
V
(mV)

NG

HG

HG
+ GD1A

-40

17.61 ± 2.60

21.71 ± 6.24

9.16 ± 1.93*

-30

10.02 ± 0.67

14.26 ± 2.49

10.50 ± 3.04

-20

7.88 ± 0.74

5.84 ± 0.58

5.68 ± 0.99

-10

4.65 ± 0.36

3.60 ± 0.32

3.43 ± 0.61

0

3.17 ± 0.21

2.34 ± 0.28

2.16 ± 0.36

10

2.25 ± 0.17

1.55 ± 0.16

1.56 ± 0.26

20

1.71 ± 0.19

1.15 ± 0.13

1.12 ± 0.16*

30

1.41 ± 0.23

0.97 ± 0.11

0.97 ± 0.14

Table 30. Addition of GD1A did not affect activation kinetics.

Activation time constants (τon) from HEK-α1H cells; NG (n=9), HG (n=10), HG + GD1A (n=9); data
shown are mean ± SEM. *p<0.05 compared to NG data, one-way ANOVA.
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τoff (ms)
V
(mV)

NG

HG

HG
+ GD1A

-40

125.12 ± 23.77

91.47 ± 29.78

70.28 ± 11.60

-30

41.99 ± 2.27

30.24 ± 3.29

39.99 ± 6.58

-20

31.23 ± 2.10

22.67 ± 1.78*

24.32 ± 2.03*

-10

26.39 ± 1.53

20.07 ± 1.47*

19.48 ± 1.43*

0

23.24 ± 1.08

18.36 ± 1.27*

17.35 ± 1.12*

10

21.14 ± 1.06

17.39 ± 1.04*

16.24 ± 1.10*

20

20.37 ± 1.43

17.26 ± 0.98

15.98 ± 1.10*

30

23.99 ± 3.32

20.28 ± 2.40

16.21 ± 1.06

40

34.30 ± 8.08

22.45 ± 3.99

20.38 ± 2.65

Table 31. Addition of GD1A did not affect inactivation kinetics.

Inactivation time constants (τoff) from HEK-α1H cells; NG (n=9), HG (n=10), HG + GD1A (n=9); data
shown are mean ± SEM. *p<0.05 compared to NG data, one-way ANOVA.
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τdeac (ms)
V
(mV)

NG

HG

HG
+ GD1A

-60

3.60 ± 0.20

5.24 ± 0.95

5.92 ± 0.84

-70

3.76 ± 0.41

8.68 ± 2.06*

3.78 ± 0.34

-80

5.38 ± 1.86

9.00 ± 1.64

4.41 ± 0.80

-90

4.77 ± 0.96

5.15 ± 1.18

4.23 ± 0.28

-100

3.10 ± 0.26

4.12 ± 0.49

3.26 ± 0.18

-110

3.49 ± 0.40

3.57 ± 0.44

3.37 ± 0.36

-120

4.20 ± 0.94

3.15 ± 0.51

3.00 ± 0.34

-130

3.20 ± 0.39

3.35 ± 0.60

3.52 ± 0.41

-140

3.62 ± 0.52

2.44 ± 0.50

3.72 ± 0.63

Table 32. Addition of GD1A did not affect deactivation kinetics.

Deactivation time constants (τdeac) from HEK-α1H cells; NG (n=9), HG (n=10), HG + GD1A
(n=9); data shown are mean ± SEM. *p<0.05; one-way ANOVA.
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Figure 35. Addition of GD1a did not affect CaV3.2 open probability in HEK-α
α1H cells
incubated in high glucose medium.

(A) Protocol and representative calcium tail current evoked by a 12 ms depolarizing pulse from
VH= -90 mV to VP= -90 to 0 mV, followed by hyperpolarization to VT= -100 mV in HEK-α1H cells.
(B) Steady state activation curves obtained from cells cultured in NGM (open circles; n=9), HGM
(closed circles; n=10) or HGM + GD1a (orange circles; n=9). Dashed lines indicate V50 values. (C)
Bar graph comparing steady-state activation V50 values from B. Data shown in B and C are mean
± SEM. *p<0.02 compared to NG (unpaired Student's t-test). HG+GD1a V50 value is not significant
when compared to either NG or HG data.
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Figure 36. Addition of GD1a did not affect CaV3.2 availability.

(A) Protocol and representative calcium current traces evoked by a 1.5 s depolarizing pulse from
VH= -90 mV to VP= -110 to 0 mV, return to VH for 20 ms, followed by depolarization to VT= -30 mV
for 150 ms. (B) Steady state inactivation (SSI) curves obtained from cells cultured in NGM (open
circles; n=9), HGM (closed circles; n=10), or HGM + GD1a (orange circles; n=9). (C) Bar graph
comparing V50 values from the curves in B. Data shown in B and C are mean ± SEM. Observed
differences were not statistically significant (p>0.05; one-way ANOVA).
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SSA V50
(mV)

NG

HG

HG
+ GD1A

-23.91 ± 1.28

-30.76 ± 1.51*

-27.45 ± 1.83

Table 33. Effect of GD1A on steady-state activation V50 values from HEK-α
α1H cells.

NG (n=10), HG (n=10), HG + GD1A (n=9); *p<0.05 compared to NG data (one-way ANOVA). HG
+ GD1a data is not significant when compared to either NG or HG data.

SSI V50
(mV)

NG

HG

HG
+ GD1A

-50.43 ± 0.90

-52.22 ± 1.03

-54.64 ± 1.55

Table 34. Effect of GD1A on steady-state inactivation V50 values from HEK-α
α1H cells.

NG (n=10), HG (n=10), HG + GD1A (n=9). Differences are statistically insignificant (p>0.05; oneway ANOVA).
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GM1 colocalized with the CaV3.2 T-type calcium channel
Sandra Briseño and Dr. Piedras-Rentería used a confocal imaging
approach to determine if CaV3.2 channel proteins co-localize with the ganglioside
GM1.

Using immunocytochemistry, HEK-α1H cells cultured in normal glucose

medium were fixed and treated with FITC-conjugated CtxB, which targets to GM1
in the membrane (Figure 37, Panel A; green), and polyclonal anti-α1H antibodies
with Alexa-594-conjugated secondary antibodies to detect the CaV3.2 protein
(Panel B; red). CaV3.2 and GM1 show colocalization (Panel C; yellow). The fact
that GM1 and the α1H calcium channel visually colocalize corroborates our data
showing a functional interaction between the two.

Discussion
It has been previously established that T-type calcium channels
(particularly CaV3.2) are crucial in pain pathways (Todorovic et al. 2002; Kim et
al. 2003; Bourinet et al. 2005; Nelson et al. 2006; Choi et al. 2007) and likely
mediate the development of chronic or neuropathic pain (Matthews et al. 2001;
Dogrul et al. 2003; Flatters et al. 2004; Bourinet et al. 2005; Pathirathna et al.
2005; Jagodic et al. 2007; Messinger et al. 2009; Zamponi et al. 2009). Here I
focused on the specific effects of altered membrane GM1 composition on CaV3.2
calcium channels, which has not been previously addressed. In this chapter, I
have shown that the monosialoganglioside GM1 is a specific inhibitory modulator
of CaV3.2.
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B

A

C

Figure 37. Colocalization of GM1 with CaV3.2 in HEK-α
α1H cells.

Cellular distribution of GM1 (Panel A; green) in HEK-293 cells stably transfected with CaV3.2 Ttype calcium channels (Panel B; red). In merge (Panel C), colocalization of GM1 with CaV3.2 is
shown by yellow color. GM1 was detected with FITC-conjugated CtxB; CaV3.2 was detected with
anti-α1H polyclonal antibodies.
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First, I showed that current density is increased in cells cultured in
hyperglycemic conditions, which is in agreement with several reports from both in
vitro and in vivo studies on T-type calcium channels (Li et al. 2005; Jagodic et al.
2007; Latham et al. 2009; Messinger et al. 2009; Shankarappa 2010;
Shankarappa et al. 2011). This increase in current density is not due increased
gene expression in our case, as the channel is expressed via an exogenous
promoter system. The data showing that GM1, but not GD1a, decreases current
density in cells cultured in high glucose conditions, and the fact that it is
completely reversible with further addition of CtxB, show that GM1 is a direct
modulator of CaV3.2 calcium channels. This is corroborated by similar reports
showing that GM1 modulates L-type voltage-gated calcium channels (Hilbush et
al. 1992; Carlson et al. 1994; Wu et al. 1996); likewise, it is supported by studies
showing that intracellular calcium levels and calcium fluxes are altered by GM1,
possibly by alterations in membrane fluidity or calcium permeability (i.e. via
voltage-gated calcium channels) (Dixon et al. 1987; Guérold et al. 1992; Milani et
al. 1992; Gouy et al. 1994; Buckley et al. 1995).

The reports suggest that

voltage-gated calcium channels are likely involved, but rule out L- and N-type
channels because their specific inhibition has no effect on the fluxes. Modulation
by GM1 could be through direct interaction with the channel, or indirect, such as
through kinase regulation. Our data showing that direct addition of CtxB to cells
cultured in normal glucose medium disinhibited CaV3.2, elevating current density
to levels seen in cells cultured in HGM again supports the idea that GM1 is a
direct inhibitory modulator of the channel, and is likely converted to more
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complex gangliosides during hyperglycemic conditions thereby releasing the
inhibition. The specific location of NANA moieties in gangliosides may be an
important factor regarding their ability to inhibit CaV3.2 channels. For example,
GM1 has one sub-terminal NANA moiety, whereas GD1A has both a terminal and a
sub-terminal NANA moiety. The presence of the terminal NANA moiety may
create steric hindrance, prohibiting interaction with CaV3.2 and releasing channel
inhibition.
Next, I showed that inactivation kinetics are accelerated in cells cultured in
HGM, which can be reversed by the addition of GM1, but not with GD1a. This
effect can be removed with further addition of CtxB, showing that GM1 is a
specific modulator of CaV3.2 channel inactivation. This conclusion is bolstered
by the data in cells cultured in NGM showing that addition of GM1 had no effect
on inactivation kinetics, as there is already plentiful GM1, and that GM1
sequestration with CtxB is associated with accelerated inactivation kinetics,
similar to cells cultured in HGM.
In vitro culture conditions in HGM resulted in increased channel open
probability. While addition of CtxB to cells cultured in NGM reproduced this shift,
GM1 replenishment to cells cultured in HGM did not reverse the increased CaV3.2
open probability.

Addition of CtxB efficiently precluded the ability of GM1 to

interact with CaV3.2 channels in cells cultured in normal glucose medium. On the
other hand, exogenously added GM1 may not necessarily integrate into regions of
the membrane where it could interact with the channel in such a way to affect
open probability.

If this were the case, it is possible that increasing the

concentration of GM1
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added could lead to a change in open probability. A more

likely explanation is that there is a concomitant change occurring in
hyperglycemia that also affects open probability, such as channel glycosylation.
I hypothesize that GM1 levels and channel glycosylation exert an additive
effect on channel open probability, where low channel glycosylation and high GM1
levels in the membrane lead to a more positive V50 value, such as in the case of
cells cultured in NGM. Channel glycosylation and/or a decrease in membrane
GM1 content were associated with a more negative V50 value, as is seen in cells
incubated in HGM.

Addition of GM1 to the membrane of these cells did not

change the glycosylation status of the channel, and therefore it was not
associated with a decrease in open probability. On the other hand, treatment of
cells cultured in HGM with neuraminidase both decreased the number of sialic
acid moieties on channel glycans and increased membrane GM1 content and, as
expected from this hypothesis, was in fact associated with a more positive V50
value. However, the change in open probability observed with neuraminidase
treatment was only accomplished when current density changes were lower than
those observed in euglycemia, suggesting that the gangliosides and N-glycans
are de-sialylated at with different efficacies, with the gangliosides likely being
desialylated before the N-glycans.
Our results demonstrating that channel availability is increased in cells
cultured in high glucose (but not normal glucose) after treatment with GM1
suggest that there is a concomitant change occurring in hyperglycemia that is
evidenced only with GM1 addition or neuraminidase treatment, which removes
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sialic acids from proteins and from complex gangliosides, effectively turning them
into GM1 (Wu et al. 1991). This result could be due to alteration of channel
glycosylation status or to a concomitant change that was not addressed in this
study.

Perhaps there is an additive effect between the altered glycosylation

status of the lipids and the proteins, in which altered channel glycosylation (cells
in HGM) or high membrane GM1 content (cells in NGM) alone have no significant
effect on channel availability, but when they are combined, as in cells incubated
in HGM with added GM1, there is an appreciable effect. The data showing that
cells incubated in HGM and treated with Neu also have increased channel
availability may suggest that the type of glycan added to the protein during
glycosylation may be different than in normal physiological conditions.
In contrast to our results, some in vivo reports shown an increase in
channel availability in hyperglycemia in small (Shankarappa et al. 2011) and
medium-sized (Jagodic et al. 2007) DRG neurons from diabetic rats, while other
groups observe no change in channel availability (Ristic et al. 1998; Messinger et
al. 2009). This discrepancy in results may be due to the different experimental
conditions. While these studies all use rat DRG neurons, each study uses them
after a different duration of diabetes, varying from 10 days to 10 weeks. Perhaps
the differences in results are a product of other complications occurring with a
longer duration of diabetes and hyperglycemia, such as flux through the
advanced glycation end-product pathway or others described in part seven of
chapter one.
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Many groups have shown that membrane composition is altered in
diabetes (Pratt et al. 1969; Kumar et al. 1993; Gerbi et al. 1998; Saito et al. 1999;
Kamboj et al. 2009; Yee et al. 2010) including data showing that membrane GM1
is depleted in hyperglycemia (Cho et al. 2010); the latter substantiates our data
showing that addition of GM1 to cells cultured in hyperglycemia conditions
effectively reverses the changes seen in current density and kinetic properties.
This hypothesis is further supported by our data showing that addition of GM1 to
cells cultured in NGM has no apparent effect any of the measured parameters,
as we hypothesize that the membrane already contains plentiful GM1, in
quantities high enough to saturate sites of interaction with CaV3.2 and therefore
further addition of GM1 has no additional effect.
GM1 may be an effective inhibitor due to the location of NANA on the
internal galactose moiety. The presence of one or more NANA moieties on the
terminal galactose (such as in GD1a) may induce steric or charge-induced
hindrance so that the ganglioside can no longer interact with the channel. By this
mechanism, gangliosides with two or more NANA moieties attached to the
internal galactose (such as GD1b or GT1c) may also be able to inhibit channel
function in a similar way to GM1, if they do not have NANA moieties on the
terminal galactose.
We have looked at CaV3.2 channel properties in isolation from outside
factors such as interaction with astrocytes, myelin, or hormones, or innumerable
other factors present in the body that could alter channel activity. Based on this
study, we propose that depletion of GM1 in hyperglycemia due to increased
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conversion to di-, tri-, or oligo-sialogangliosides mediates the increased CaV3.2
calcium current density, accelerated τoff values, and increased CaV3.2 open
probability. The enhanced current density could be due to increased negative
charges in the channel’s microenvironment that affect voltage-sensitive elements
of the channel or increase local cation concentration (Schmidt et al. 1987;
Bennett et al. 1997; Marban et al. 1998), however the changes in kinetic and
steady-state properties suggest a direct modulatory interaction of GM1 with the
channel.

CHAPTER FIVE
SUMMARY
Diabetes Mellitus is a group of metabolic disorders affecting almost 26
million Americans in which blood glucose levels are abnormally high. In this
disorder, there are alterations to many bodily systems, including the nervous
system. In fact, 60-70% of patients with diabetes eventually develop nervous
system damage, a condition known as neuropathy; changes in neuronal
excitability are central to development of this condition.
CaV3.2 T-type calcium channels are crucial in controlling excitability, and
are critical in pain pathways and in the development of chronic or neuropathic
pain, especially in diabetes. Numerous groups have shown an increase in T-type
calcium current density in sensory neurons of diabetic animals or in
hyperglycemic cell cultures; however, no mechanism has yet been shown for this
alteration.
In this thesis, we showed that increased CaV3.2 T-type calcium current
density in hyperglycemia is accompanied by an increase in channel open
probability.

These changes were reversible with neuraminidase treatment,

showing that increased sialic acids attached to the channel itself or to
gangliosides in its immediate proximity are crucial for determining CaV3.2
properties in hyperglycemia in vitro.

Addition of GM1 to the membrane also
144
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reversed the increased current density, which shows that an endogenous
function of GM1 is as an inhibitory modulator of the channel. Treatment with GM1
did not reverse the enhanced open probability in hyperglycemia, suggesting that
there is an alteration to the oligosaccharide chain(s) attached to the α1H calcium
channel via N-glycosylation, which is responsible for controlling open probability.
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